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Abbreviations and definitions 
AJCC American Joint Committee on Cancer; established in 1959 to formulate 
and publish systems of classification of cancer, to be used for selecting the 
most effective treatment, determining prognosis, and continuing 
evaluation of cancer control measures 
BilIN Biliary intraepithelial neoplasia; a classification of increasing degrees of 
dysplasia and in situ neoplasia in the bile duct (BilIN1-3) similar to 
dysplasia in the pancreatic ducts (PanIN1-3) 
CDX2 caudal type homeobox 2; an intestine-specific nuclear transcription factor 
encoded on chromosome 13q; selectively expressed in gastrointestinal 
mucosa; frequently expressed in adenocarcinomas of the colon and small 
intestine, and more seldom expressed in pancreatic and biliary carcinomas 
CK cytokeratin; cytokeratins are intermediate filaments that form part of the 
cytoskeleton and consist of at least 20 subtypes, which are expressed 
differently in epithelia during the course of terminal differentiation and 
may thus be used to classify different types of epithelia; cytokeratin 
expression is often retained during malignant transformation and may 
therefore be used as evidence of the cancer origin 
CK7 cytokeratin 7; an intermediate filament often expressed by simple 
epithelia; a large and relatively basic type II cytokeratin encoded on 
chromosome 12q 
CK20 cytokeratin 20; an intermediate filament often expressed by simple 
epithelia; a small and acidic type I cytokeratin encoded on chromosome 
17q 
IPMN Intraductal papillary mucinous neoplasm; a grossly visible, non-invasive 
mucin-producing, predominantly papillary or rarely flat epithelial 
neoplasm arising from the main pancreatic duct or branch ducts, with 
varying degrees of ductal dilatation; IPMNs may be differentiated into 
gastric, intestinal, pancreatobiliary, and oncocytic types 
MCN Mucinous cystic neoplasm; a pre-neoplastic lesion consisting of ovarian-
type stroma and epithelial lining with varying degrees of atypia that may 
occasionally progress to invasive adenocarcinoma 
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MUC mucin; mucins are large extracellular proteins that are heavily 
glycosylated and function both as a barrier at epithelial surfaces and 
engage in signal transduction; altered mucin expression and glycosylation 
may be important in cancer development by influencing for example 
cellular growth, differentiation, adhesion, and invasion; mucins may be 
used both as diagnostic markers and as therapeutic targets for cancer 
MUC1 cell surface associated mucin 1; a membrane-bound glycoprotein; 
encoded on chromosome 1q 
MUC2 oligomeric mucus/gel-forming mucin 2; a secreted glycoprotein; forms an 
insoluble mucous barrier that protects the gut lumen; encoded on 
chromosome 11p 
MUC4 cell surface associated mucin 4; a membrane-bound glycoprotein 
(secreted isoforms may also exist); encoded on chromosome 3q  
PanIN Pancreatic intraepithelial neoplasia; a classification of increasing degrees 
of dysplasia and in situ neoplasia in the pancreatic ducts (PanIN1-3); 
development of most ductal pancreatic carcinomas are believed to follow 
a sequence of genomic changes that are reflected by increasing grades of 
PanIN, subsequently leading to infiltrating and/or metastasising 
carcinomas if left untreated 
R Residual tumour classification; R0, curative resection; R1, microscopic 
evidence of residual tumour; R2, macroscopic residual tumour 
study hospital Rikshospitalet University Hospital; from January 2009, “Oslo University 
Hospital, Rikshospitalet”, due to the merger of three university hospitals 
TNM Tumour, Node, Metastases; the most widely used system for classifying 
the extent of cancer spread 
UICC Union Internationale Contre le Cancer (International Union Against 
Cancer); the only international non-governmental organisation dedicated 
exclusively to the global control of cancer; founded in 1933; unites 262 
cancer organisations in over 80 countries 
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Synopsis 
Pancreatic cancer is one of the most lethal of all common cancers, with almost equal 
mortality and incidence rates. Despite vast improvements in basic understanding of this 
disease, and improvements in surgical and medical care for these patients, there has been 
little improvement in relative survival over the past half century. Symptoms often present 
late, and most tumours are not resectable at the time of diagnosis. Pancreatoduodenectomy, 
i.e. surgical removal of the pancreatic head, duodenum, and distal bile duct, has since the 
1980s evolved to become a relatively safe procedure when performed at specialised centres, 
and is the treatment of choice for clinically resectable masses in the pancreatic head. 
However, even after assumed margin-free pancreatoduodenectomy for adenocarcinomas, 
most patients die within few years due to local recurrence or systemic spread of the 
malignant disease. Furthermore, the use of neoadjuvant, adjuvant, or palliative chemo- 
and/or radiotherapy has demonstrated very limited effect on long-term survival, and new 
treatments are urgently needed.  
Long-term survival after curative-intent pancreatoduodenectomy depends on 
histopathological tumour characteristics such as presence of lymph node involvement, 
perineural infiltration, and the particular histologic subtype, as well as completeness of 
surgical tumour removal. The reported rates of identified adverse prognostic factors upon 
histopathological assessment, for instance resection margin involvement, are often low, and 
this may indicate underreporting of adverse prognostic factors in pancreatoduodenectomy 
series and clinical trials. Furthermore, tumours that involve the pancreatic head do not 
always originate from the pancreatic head itself, and prognostically more favourable 
tumours that arise from the distal bile duct, ampulla of Vater, or peri-Vaterian duodenum 
may sometimes be misdiagnosed as pancreatic carcinomas. Survival estimates in clinical 
studies may thus be biased by insufficient quality control on histopathology, possibly due to 
lack of standardisation of the histopathologic assessment. 
The aims of the present thesis were to evaluate to what extent standardised 
histopathologic assessment of pancreatoduodenectomy specimens influences on 
histopathologic reporting and survival estimates, and to report on prognostic factors in a 
setting of standardised histopathologic assessment. Particular focus has been on evaluation 
of the resection margins and tumour origin. The patients included were all those who 
underwent pancreatoduodenectomy at the study hospital (Rikshospitalet University 
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Hospital) 1980-2004, as well as all those who underwent pancreatoduodenectomy in 
Norway 1998-2004 as reported to the Cancer Registry of Norway. Four studies are included 
in the present thesis. In all four studies, we analysed associations between histopathological 
tumour characteristics and overall patient survival. In the first and third study, we performed 
slide review and review of histopathologic reports from resections at the study hospital. The 
second study was based on review of histopathologic reports, and the fourth study made use 
of immunohistochemistry on tissue microarrays from tumours resected at the study hospital. 
Taken together, the four studies demonstrate that standardised histopathologic 
assessment and reporting of pancreatoduodenectomy specimens is necessary for 
completeness of histopathologic reporting, to avoid underestimation of resection margin and 
lymph node involvement, to avoid misdiagnosis of tumours originating from the ampulla of 
Vater (or distal bile duct or duodenum), and to obtain accurate and reliable survival 
estimates. Furthermore, standardisation of histopathologic reporting seems to be particularly 
important with respect to assessment of lymph node involvement. 
Second, the studies demonstrate that adenocarcinomas in the pancreatic head, distal 
bile duct, ampulla of Vater, and peri-Vaterian duodenum may be classified by their 
histologic type of differentiation, pancreatobiliary versus intestinal, as an adjunct to 
classification by the assumed anatomic tumour origin. The true origin of adenocarcinomas 
involving the pancreatic head may sometimes be impossible to determine with certainty, 
whereas the histologic type of differentiation, which often resembles the tumour origin, is 
easier to determine (and does not require immunohistochemical evaluation). Moreover, the 
histologic type of differentiation was found to be an independent predictor of long-term 
survival. Third, the studies indicate that immunostaining of pancreatobiliary-type tumours 
targeting MUC1 and MUC4 may be used to identify a subgroup of patients with a 
particularly poor prognosis after curative-intent pancreatoduodenectomy. 
This work confirms the need for standardising histopathologic evaluation and 
reporting after pancreatoduodenectomy and documents that adenocarcinomas that involve 
the pancreatic head should be classified by their histologic type, pancreatobiliary or 
intestinal (or other), in addition to classification by tumour origin (pancreas, distal bile duct, 
ampulla, or duodenum). Furthermore, the heavily glycosylated membrane-bound mucins 
MUC1 and MUC4 seem to be associated with a particularly poor prognosis for patients with 
pancreatobiliary-type differentiated adenocarcinomas. These proteins should be examined 
further in pursuit of new treatments for pancreatic cancer. 
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General introduction 
Pancreatic cancer has the poorest relative survival among the common cancers1-3. Most 
pancreatic cancers are ductal adenocarcinomas, and the commonest location within the 
pancreas is the pancreatic head4. Surgical resection is at present the only curative treatment 
option, but these carcinomas are often diagnosed at an advanced stage, and curative-intent 
pancreatoduodenectomy is thus only performed for 10-15% of pancreatic head 
adenocarcinomas5. Even after curative-intent pancreatoduodenectomy, most patients die 
within few years6-9, due to local recurrence or systemic spread10-13. Extended surgical 
procedures and adjuvant chemo- and radiotherapy regimens have not been shown to 
influence considerably on long-term survival14-17, although adjuvant chemotherapy has 
indeed been shown to prolong life with approximately one quality-adjusted life month18,19. 
Therefore, new treatments are urgently needed20. Current understanding of the biology and 
mechanisms of spread for these adenocarcinomas is rapidly increasing5,20-22. However, 
histopathologic evaluation of the pancreatoduodenectomy specimen is often non-
standardised23-25, and poor quality control on histopathology may thus bias the results in 
multi-centre studies aiming at evaluating new treatments17,26-29. 
Adenocarcinomas confined to the pancreatic head may originate from pancreatic, 
ampullary, distal bile duct, or peri-Vaterian duodenal tissue, and failure to reach a correct 
diagnosis of the cancer origin may lead to false assumptions regarding long-term 
survival25,30-32. Staging according to the TNM criteria relies on a correct diagnosis of the 
cancer origin, and staging criteria are different for the separate origins33,34. The World 
Health Organization’s recommendations for classification of these tumours35 also includes 
classification according to a morphologic diagnosis, i.e. the histologic type. In the present 
work, we have reported prognostic data from curative-intent pancreatoduodenectomy for 
adenocarcinomas originating from these four locations evaluating at the same time the 
importance of standardising histopathologic evaluation and reporting, with particular focus 
on evaluation of resection margin involvement, tumour origin, and histologic type of 
differentiation. 
Epidemiological aspects 
Pancreatic cancer affects both sexes with a sex ratio close to one (slightly higher for men 
than women), and is the thirteenth commonest cancer of the world1. The incidence is 
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strongly age-dependent, affecting very few before 40 years of age, and has a peak in 
incidence ratios around 70-75 years2,3. The age-standardised incidence rate is between 4.5 
and 9 per 100,000, and the estimated number of deaths per year worldwide due to pancreatic 
cancer is 227,0001. Incidence and mortality rates are higher in developed than developing 
countries, but this is probably best explained by differences in diagnostic capacity rather 
than aetiology1,36. Pancreatic cancer has the highest ratio of mortality to incidence (98%), 
but due to its relatively low incidence, it is only the eighth most common cause of death 
from cancer worldwide1. In Western countries, pancreatic cancer is the fourth or fifth 
leading cause of cancer-related death, and the second most frequent gastrointestinal cancer, 
only preceded by colorectal cancer2,37. Temporal studies have shown that the incidence of 
pancreatic cancer has been relatively stable over the last forty years, although some reports 
have shown an increase in incidence during the 1970s and 1980s and subsequently a decline 
and levelling-off during the last decades2,38-41. The peak in incidence occurred 
approximately a decade earlier for men than women, paralleling to some extent changes in 
smoking habits36,42-44. 
Cigarette smoking is in fact the strongest known environmental risk factor for 
pancreatic cancer, increasing the risk approximately two-fold and causing about 25% of the 
total burden of this tumour42-44. However, the trends in incidence of pancreatic cancer can 
only partly be explained by changes in smoking habits, and other factors must therefore be 
involved in development of pancreatic cancer5,21,42,45. Although risk factors associated with 
pancreatic cancer have been extensively explored, the causal factors for pancreatic cancer 
remain elusive. Studies have indicated that dietary factors, high fat intake, obesity, high 
alcohol consumption, and chronic pancreatitis may increase the risk of pancreatic cancer, 
but the results from such studies have been contradictory and inconclusive42,45-47. More 
convincingly, diabetes type II48, and in particular recent-onset diabetes49, has been 
suggested to increase the risk of pancreatic cancer. Although pancreatic cancer may induce 
substantial inflammation and thus cause pancreatitis and diabetes50-52, the link between 
diabetes and pancreatic cancer is probably a causal rather than a consequential association48. 
However, only about 1% of patients who develop type II diabetes will be diagnosed with 
pancreatic cancer within 3 years of first meeting criteria for diabetes49.  
About 5-10% of pancreatic cancers are thought to be directly attributable to genetic 
factors53,54. Several genetic syndromes are associated with an increased risk of pancreatic 
cancer, including hereditary breast and ovarian cancer syndrome, familial atypical multiple 
mole melanoma syndrome (FAMMM), Peutz-Jeghers syndrome, and hereditary pancreatitis. 
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However, these syndromes account for very few of the total number of patients who develop 
pancreatic carcinomas. Most patients with hereditary pancreatic cancer have unknown 
genetic alterations, probably several accumulated, low-penetrant genetic alterations54. These 
genetic changes, as well as changes seen in sporadic pancreatic cancers, may increase the 
risk of pancreatic cancer by increasing susceptibility to environmental factors such as 
smoking55. Knowledge about molecular mechanisms and signalling pathways involved in 
pancreatic cancer has increased rapidly in recent years22,56, although key features to derive 
effective prevention and treatment strategies for pancreatic cancer remain enigmatic. 
Adenocarcinomas that involve the pancreatic head may sometimes derive from the 
distal bile duct, ampulla of Vater, or peri-Vaterian duodenum32. These tumours, particularly 
the ampullary and duodenal tumours, have a more favourable prognosis compared to 
pancreatic ductal adenocarcinomas6,32,57,58. In pancreatoduodenectomy series, pancreatic 
ductal carcinoma is generally considered the most frequent type among pancreatic, biliary, 
ampullary, and duodenal tumours6,31,57-61. However, misclassification of tumour origin has 
been demonstrated in up to one-third of long-term survivors62. The considerable variation in 
the reported relative incidences of tumours with respect to these four origins may thus 
reflect varying methods and standards in determination of the tumour origin rather than real 
differences in the relative incidences for pancreatic, biliary, ampullary, and duodenal 
tumours23. Importantly, reports on long-term survival after pancreatoduodenectomy for 
ductal pancreatic carcinomas may be biased by inadvertent inclusion of these prognostically 
more favourable tumours misdiagnosed as ductal pancreatic carcinomas25,62-64. 
Surgical aspects 
Pancreatic and periampullary anatomy 
The pancreas is an oval-shaped organ located in the posterior upper part of the abdomen, 
with a larger end (the pancreatic head) adjacent to the descending part of the duodenum, and 
with a tail towards the spleen (Figure 1, 2, and 3). The body (corpus) of the pancreas lies 
between the head (caput) and tail (cauda). The head represents approximately two-thirds of 
the pancreatic volume65 and is, by convention, delimited from the pancreatic body by the 
left border of the superior mesenteric vein, whereas the left border of the aorta delimits the 
body from the tail66. The border between the head and body (anterior to the superior 
mesenteric vein and beginning of the portal vein) is referred to as the pancreatic neck65. The 
posterior-lateral protrusion of the pancreatic head, curving behind the superior mesenteric 
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artery and vein (where there may be an indentation known as the vascular groove or 
pancreatic notch), is designated the uncinate process (Figure 2)65. 
Figure 2 
The pancreas and duodenum from 
behind.  
Henry Gray (1821–1865), Anatomy of the 
Human Body, 1918 (copyright expired), 
slightly modified (arteries, red; veins, blue; 
bile duct, green). 
Figure 3 
The pancreatic duct.  
Henry Gray (1821–1865), Anatomy of the 
Human Body, 1918 (copyright expired). 
Figure 1 
The duodenum and pancreas.  
Henry Gray (1821–1865), Anatomy of the 
Human Body, 1918 (copyright expired), 
slightly modified (pancreas, yellow). 
Most of the pancreatic tissue mass (80-90%) is composed of exocrine acinar and 
ductal cells that contribute in protein and carbohydrate digestion by secretion of digestive 
enzymes into the gastrointestinal tract in response to stimuli from the stomach and 
duodenum21,65,67. Scattered throughout the exocrine tissue are endocrine cells gathered in 
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clusters called Islets of Langerhans (Figure 4). These endocrine cells are involved in 
glucose homeostasis by secretion of hormones such as insulin and glucagon into the 
bloodstream.  
Figure 4 
Section of pancreas of dog (X 250).  
Henry Gray (1821–1865), Anatomy of the Human 
Body, 1918 (copyright expired). 
The enzyme-secreting acinar cells (from Latin, acinus, grape), so named because of 
their organisation in bundles resembling a cluster of grapes, are arranged around a central 
duct and interconnected by interlobular ducts. The ductal cells add mucous and bicarbonate 
to the enzyme mixture and form a network of increasing size, culminating in the major 
pancreatic duct (of Wirsung) and the minor (accessory) pancreatic duct (of Santorini) 
(Figure 3)68. These two large collecting ducts empty into the duodenum at the major papilla 
(of Vater) and at the minor papilla, respectively69. (See notes on terminology, particularly 
regarding the use of eponymous terms, page 25.) 
The common bile duct enters into the pancreas from behind (Figure 2) and runs 
through the pancreatic head to join (in 40-90% of cases70) with the major pancreatic duct, 
forming the hepatopancreatic ampulla (of Vater) (see notes on terminology, page 24). There 
is, however, considerable variation in the normal anatomy of these ductal structures70. The 
adult pancreas, distal bile duct, and ampulla of Vater are embryologically derived from the 
endodermal lining of the duodenum (Figure 5). The major pancreatic and common bile 
ducts do not always fuse to form a common channel, the length of which may vary from 0 to 
3.3 cm, and the orifices of the two ducts may be divided by a septum. Furthermore, there 
may or may not be dilation of the common channel (ampulla, strictly defined, is a flask-like 
dilatation of a tubular structure71), and the normal anatomy of the Vaterian system may be 
distorted by carcinoma, inflammation, or fibrosis70. 
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Figure 5 
Pancreas of a human embryo of five weeks (left) and at end of sixth week (right). 
Henry Gray (1821–1865), Anatomy of the Human Body, 1918 (copyright expired). 
Surgical resection of ductal adenocarcinomas in the pancreatic head 
Ductal adenocarcinoma and its variants are the most common neoplasms in the pancreas 
(85-90% of all pancreatic neoplasms)4, and unfortunately the most deadly65. About 60-70% 
of pancreatic ductal adenocarcinomas are found in the head of the gland4. This number 
corresponds to the size of the pancreatic head (two-thirds, see above) relative to the 
remaining pancreas and does not represent an actual over-occurrence of tumours at this 
location. Tumours in the body and tail, however, often present at a later stage and are less 
often resectable4. When preoperative work-up including imaging has demonstrated that a 
mass in the pancreatic head is surgically resectable72-74, the procedure of choice is a 
pancreatoduodenectomy75, often referred to as the Whipple procedure (named after Allen 
Oldfather Whipple, 1881-1963, who popularised this procedure during the 1930s and 
1940s76,77). Due to the complexity of this procedure, this is most often performed as a 
laparotomy although some minimally invasive pancreatoduodenectomies have also been 
described78-85. 
A pancreatoduodenectomy (see notes on terminology, page 27) involves surgical 
removal of the pancreatic head, duodenum, and distal common bile duct with the gall 
bladder (Figure 6). The head of the pancreas and the duodenum share the same arterial 
blood supply, so both these organs must be removed. The distal stomach may or may not be 
resected, depending on the type of pancreatoduodenectomy employed (classical as opposed 
to pylorus-preserving pancreatoduodenectomy). Resectable tumours involving the 
pancreatic head may originate either from the pancreatic head itself or from the distal bile 
duct, ampulla of Vater, or peri-Vaterian duodenum32,35,86, as mentioned previously. The 
origin is often impossible to determine prior to surgery, and by convenience, the four 
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separate tumours are often collectively referred to as “periampullary adenocarcinomas”6,32 
(see notes on terminology, page 23). 
Figure 6 
A pancreatoduodenectomy specimen, 
fresh from surgery, studied by the 
surgeons prior to performing the final 
anastomoses that complete this 
procedure. 
Surgical resection is at present the only curative treatment option for these tumours. 
However, the disease often presents at an advanced stage, and only 10-15% of pancreatic 
head adenocarcinomas are offered potentially curative surgery, although a continuous 
improvement in surgical technique and intensive care has made it possible to offer surgery 
to an increasing number of patients5. Surgical mortality was considerable until the 1980s, 
after which operative mortality has declined to less than 5% in most high-volume and 
specialised centres, with acceptable although still considerable morbidity87. Even in the very 
elderly, pancreatoduodenectomy may now be performed as a relatively safe procedure88-91. 
Pancreatoduodenectomy may be performed as a standard (classical)77 or pylorus-
preserving92 Whipple procedure, with similar morbidity and mortality93. The procedure may 
include extended lymph node dissection14,94-96, although at a higher risk, and this should 
thus only be performed in clinical trials, if at all14,97,98. Vascular resection may be required 
in order to obtain free resection margins if the tumour involves the portal or mesenteric 
veins98-103. Although adding to the complexity of this already lengthy and difficult 
operation, pancreatoduodenectomy with venous resection has evolved as a relatively safe 
procedure for selected patients104. Venous involvement indicates local advancement of the 
tumour rather than a more aggressive tumour type104, and long-term survival has been 
shown to depend on the depth105 and length106 of venous involvement. Tumour extension to 
the mesenteric artery or celiac axis, however, is associated with similar long-term survival 
as for unresected patients and is generally considered a contraindication to 
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pancreatoduodenectomy98,107, although possibly feasible for selected patients following 
neoadjuvant preoperative radiotherapy108. 
A number of studies have demonstrated that mortality and morbidity is considerably 
higher for low-volume surgical institutions and surgeons, compared to high-volume surgical 
institutions and surgeons, respectively109-116. The reason for the better outcome in high-
volume centres may not only be superior surgical technique, but also better intensive care, 
multi-disciplinary support, and administrative and financial resources in general. It could 
seem obvious that patients being evaluated for pancreatoduodenectomy at low-volume 
institutions should be referred to high-volume centres where they may undergo the best 
treatment117. However, the critics argue that community hospitals and surgeons should 
indeed perform a certain number of advanced abdominal operations in order to maintain 
sufficient competence and skills required to handle surgical urgencies when time does not 
allow referral to larger centres118,119. Moreover, the validity of studies reporting a relation 
between provider case volume and cancer mortality has been questioned due to the 
heterogeneity of results from individual studies, and a call for more direct quality measures 
has been advocated120,121. As an alternative to regionalisation of high complexity operations 
to high volume hospitals, attempts have been made to export surgical excellence from high 
to low-volume hospitals, with some success122. 
Pancreatoduodenectomy for adenocarcinomas in the pancreatic head, although 
intended as a curative procedure, in most cases turns out to be a palliative procedure, 
although some hope may be seen from recent reports123. Most patients die within few years 
even after curative-intent pancreatoduodenectomy6-9,124, due to local recurrence or systemic 
spread10-13. A microscopically margin-free resection offers patients approximately half a 
year of survival benefit compared to curative-intent pancreatoduodenectomy with 
microscopic residual disease8,11,24,57,58,87,124-137 (Table 1). 
Some investigators question whether long-term survival for pancreatic cancer may at 
all be possible25,138, and it has been suggested that “field cancerisation”139,140 of the 
pancreatic tissue may make all pancreatic ductal carcinomas virtually unresectable due to 
molecular alterations in the remaining tissue even in microscopically curative resections141. 
Considerable interest has been shown in extending surgery to remove all retroperitoneal 
tissue that could potentially harbour neoplastic cells responsible for local recurrence, and to 
harvest all lymph nodes that might also represent residual disease. Such measures have not, 
however, been shown to increase survival after pancreatoduodenectomy14,94-96. 
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Histopathological aspects  Table 2: Histological variants of 
malignant tumours of the pancreas 
Neoplasms of the pancreas may be divided into 
neoplasms with predominantly exocrine or 
predominantly endocrine differentiation65,142. 
Exocrine neoplasms may be further subdivided 
into solid and cystic tumours. Ductal 
adenocarcinoma is the most common type of 
pancreatic cancer (Table 2)5,21,143-146. These 
gland-forming epithelial neoplasms are believed 
to originate from epithelial cells lining the 
pancreatic ducts or smaller ductules. Morphologic 
features include tubular or cribriform structures, 
cysts, papillae, and mucin formation145,146. 
Glandular structures resembling normal 
pancreatic ducts are typically embedded in 
abundant desmoplastic stroma. This type of 
ductal pancreatic adenocarcinoma is sometimes 
referred to as pancreatobiliary-type adeno-
carcinoma because of its similarities to biliary 
carcinomas146. 
Malignant neoplasms of the exocrine 
pancreas 
Ductal adenocarcinomas 
- pancreatobiliary-type adenocarcinoma 
(typical type of ductal adenocarcinoma; 
also called duct cell adenocarcinoma, 
tubular-type adenocarcinoma, duct cell 
carcinoma, or simply pancreatic cancer) 
- intestinal-type adenocarcinoma 
- adenosquamous carcinoma 
- colloid (mucinous non-cystic) carcinoma 
- hepatoid carcinoma 
- medullary carcinoma 
- signet ring cell carcinoma 
- undifferentiated (anaplastic) carcinoma 
- undifferentiated carcinoma with 
osteoclast-like giant cells 
Ductal adenocarcinomas? 
- mucinous cystadenocarcinoma 
- invasive intraductal papillary-mucinous 
neoplasm (invasive IPMN) 
- mixed acinar-ductal carcinoma 
- mixed ductal-endocrine carcinoma 
- mixed acinar-endocrine-ductal 
carcinoma 
- clear cell carcinoma 
Less frequent variants of ductal adeno-
carcinoma comprise adenosquamous carcinoma, 
colloid (or mucinous non-cystic) carcinoma, 
hepatoid carcinoma, medullary carcinoma, signet 
ring cell carcinoma, undifferentiated (anaplastic) 
carcinoma, as well as undifferentiated carcinoma 
with osteoclast-like giant cells143,144. 
Non-ductal malignancies of the exocrine 
pancreas 
- serous cystadenocarcinoma 
- invasive mucinous cystic neoplasm 
- acinar cell (cystadeno)carcinoma 
- pancreatoblastoma 
- solid-pseudopapillary neoplasm 
Malignant neoplasms of the non-
exocrine pancreas 
Malignancies of the exocrine pancreas 
that are normally categorised as non-ductal 
malignancies comprise serous cystadeno-
carcinoma, mucinous cystadenocarcinoma, 
invasive intraductal papillary-mucinous neoplasm (IPMN), acinar cell 
(cystadeno)carcinoma, solid-pseudopapillary carcinoma, and pancreatoblastoma5,145,147. 
Endocrine neoplasms 
Other (rare) primary malignancies of the 
pancreas 
Secondary neoplasms 
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However, mucinous cystadenocarcinoma and IPMN may in fact have ductal origin146, and 
recently, intestinal-type adenocarcinoma has been recognised a separate type of ductal 
adenocarcinoma of the pancreas148. In addition, mixed ductal-endocrine carcinoma and clear 
cell carcinoma are sometimes classified as tumours of ductal origin5,145. 
Secondary tumours may occasionally present as pancreatic masses, due to either 
metastatic or direct spread (for example from the biliary tract or adjacent intestine). 
Pancreatic tumours may derive from cells of the non-exocrine pancreas, particularly from 
the endocrine cells in the islets of Langerhans22,147. Small cell carcinoma is considered an 
exceedingly uncommon pancreatic tumour of non-ductal origin146. The existence of this 
type has in fact been debated due to the possibility that these tumours may represent 
metastasis from for example an occult primary tumour in the lung. Small cell carcinomas 
are now classified as endocrine carcinomas (in addition to large cell endocrine 
carcinomas)149. Finally, cases of primary pancreatic lymphoma150,151 and connective tissue 
tumours such as pancreatic carcinosarcoma152 (very uncommon) have occasionally been 
reported. 
As mentioned previously, primary adenocarcinomas that involve the pancreatic head 
and may be removed by curative-intent pancreatoduodenectomy, do not necessarily derive 
from the pancreatic tissue itself. Some of these tumours originate from the adjacent 
duodenum, distal common bile duct (where it passes through the pancreatic head), or the 
hepatopancreatic ampulla (the common orifice of the bile duct and main pancreatic duct 
towards the duodenal lumen; present in 40-70% of the normal population70). Although these 
tumours have a common embryologic ancestry (Figure 5), duodenal (and ampullary) 
adenocarcinomas have a far better prognosis compared to pancreatic (and biliary) 
adenocarcinomas31,145,153-156. Interestingly, the rate of cancer development is similar in 
pancreatic, extrahepatic biliary tract, ampullary, and duodenal carcinomas, taking into 
consideration the relative surface area of the ductal system in these sites157. This may 
possibly indicate a field effect of cancerisation of these epithelia157,158.  
The particular tissue of cancer origin may in fact be difficult to determine, by strict 
anatomic considerations (Box 1)30,31,136,153,159-162, especially when the tumour involves 
several of the potential origins. For example, ampullary tumours larger than 1-2 cm are most 
likely to invade the duodenum, distal bile duct, and/or pancreas, and such relatively large 
ampullary tumours may be impossible to discriminate from invasive tumours originating 
from either of these other periampullary tissues. Furthermore, ampullary adenocarcinomas 
may have histopathological characteristics of either intestinal or pancreatic/biliary 
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pancreatic/biliary tissue31,155 – sometimes even both lines of differentiation within the same 
tumour (these carcinomas may be classified according to the predominant type30,155). 
Box 1: Determination of the tumour origin 
Determination of the origin of adenocarcinomas that involve the pancreatic head may be difficult or 
even impossible, in some cases.  
Adequate macroscopic handling and sectioning of the specimen includes preparation of a whole-
mount block that includes the distal bile duct, the pancreatic duct, and the ampulla of Vater, and the 
duodenum. Slides from this block should then be prepared by sectioning parallel to these structures 
of potential tumour origin. The tumour’s relation to each of these structures may then be evaluated 
on the same slide. 
Slide reevaluation of the tumour origin has limited value unless the slides were originally prepared 
as described above, since considerable variation in normal anatomy and tumour involvement of 
these periampullary structures may make it difficult in retrospect to distinguish between the 
separate ductal epithelia.  
Irrespective of how the slides are prepared, microscopic assessment of the tumour origin should be 
based on (1) identification of the main localization and centre of the tumour, as well as (2) the 
pattern of growth relative to periampullary anatomy, and (3) whether there are tumour associated 
changes such as dysplasia of adjacent epithelia. 
In particular, the following criteria apply: 
 Duodenal adenocarcinoma: The tumour is mainly localised in the duodenum. Dysplasia of 
duodenal epithelium is often present. Infiltration to the ampullary region and/or pancreas may 
occur. 
 Ampullary adenocarcinoma: The tumour is mainly localised in the ampullary region. 
Dysplasia in the ampullary epithelium is often present, and an associated intraampullary 
adenoma component may be present. Some tumours fill the entire ampulla, and there may be 
dilatation of the bile and/or the pancreatic ducts proximally. 
 Distal bile duct adenocarcinoma: The tumour grows inside or alongside the distal bile duct 
epithelium, often with  a fusiform growth pattern. Dysplasia of the adjacent biliary epithelium is 
often present (BilIN). There is almost always infiltration into the pancreas, and sometimes also 
into the ampullary region and/or the duodenum. 
 Ductal pancreatic adenocarcinoma: The tumour is mainly localised in the pancreas. PanIN-
changes are often present. Infiltration into the ampullary region, the distal bile duct and/or the 
duodenum may occur. 
Typically, the pancreatobiliary-type adenocarcinomas are composed of simple or branching 
glands with cuboideal epithelium and surrounded by abundant desmoplastic tissue, whereas 
intestinal-type carcinomas consist of solid nests with cribriform areas and taller, often 
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pseudostratified epithelium with basally located nuclei and often presence of mucin31,155. 
Whereas the tumour origin may be difficult to determine, the histologic type of 
differentiation may give an indication of the cancer origin30, although some tumours 
possibly derive from metaplastic or transdifferentiated epithelia. 
Molecular characterisation of neoplasms; premalignant lesions 
Molecular studies of ductal pancreatic adenocarcinomas have revealed associations with 
genetic mutations that involve activation of K-ras and inactivation of p53, p16, DPC4, as 
well as dysregulation of growth factors and growth factor receptors, and upregulation of 
matrix metalloproteinases and regulators of tumour angiogenesis163,164. Several of these 
genetic alterations have also been identified in precursor lesions of pancreatic cancer164,165. 
Three distinct precursors have been recognised165-167. First, most ductal pancreatic 
carcinomas evolve from a sequence of genetic and histologic alterations that are designated 
pancreatic intraepithelial neoplasia (PanIN) 1-3143,144,168-170. Second, intraductal papillary 
mucinous neoplasm (IPMN), which is a grossly visible, non-invasive mucin-producing, 
predominantly papillary or rarely flat epithelial neoplasm arising from the main pancreatic 
duct or branch ducts, with varying degrees of ductal dilatation, may progress to either 
mucinous non-cystic (colloid) carcinoma or ductal adenocarcinoma165,171,172. Third, 
mucinous cystic neoplasm (MCN), which consists of ovarian-type stroma and epithelial 
lining with varying grades of atypia, may progress to invasive adenocarcinoma173. Although 
these precursor lesions harbour many of the same genetic alterations, they are believed to 
represent distinct pathways to development of invasive pancreatic cancer165,166. 
 Similarly, at least two major precursor lesions have been associated with the 
development of biliary tract carcinomas. Biliary intraepithelial neoplasia (BilIN) 1-3174,175 is 
a microscopic lesion of flat or low-papillary dysplastic epithelium that may be considered 
the biliary counterpart of PanIN175-177. Second, intraductal papillary neoplasm of the bile 
duct (biliary IPN) is considered the biliary counterpart of pancreatic IPMN175,176. Ampullary 
carcinomas are believed to derive from intestinal-type mucosa or from pancreatic duct-type 
ampullary mucosa178. Ampullary carcinomas may often derive from pre-existing ampullary 
adenomas31,179 or distended glands (so-called overreplacement of the ampullary mucosa)180. 
Similar to the adenoma-carcinoma sequence theory for pancreatic (and colorectal) 
carcinoma development, ampullary and papillary carcinomas may result from a stepwise 
accumulation of genetic alterations181-187. 
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Although there are many similarities in the molecular pathogenesis and 
characteristics of pancreatic and (other) periampullary adenocarcinomas, several molecules 
are to some degree differentially expressed on the cells of pancreatic, biliary, ampullary, and 
duodenal cancers. Immunohistochemical evaluation of pancreatoduodenectomy specimens 
is sometimes used to discriminate between tumours of these separate origins, and to 
discriminate between histologic subtypes for each origin, for example between intestinal 
and pancreatobiliary subtypes of ampullary carcinomas31,155,188,189. The most commonly 
used markers of pancreatobiliary-type and intestinal-type differentiation were evaluated in 
paper IV. In particular, cytokeratins (for example CK7 and CK20) are intermediary 
filaments that are often selectively expressed in certain tissues, and the expression is often 
retained in neoplastic transformation190. The caudal-type homeobox transcription factor 
CDX2 regulates axial development and intestinal differentiation and may be used as a 
marker of intestinal morphology148,191,192. Finally, the membrane-bound mucins MUC1 and 
MUC4193-195 and the secreted gel-forming mucins MUC2, MUC5AC, and MUC6195 have 
been considered potential markers of differentiation in the gastrointestinal tract196. These 
mucins are large glycoproteins that function both as epithelial barriers and engage in signal 
transduction195,197,198. They are important in cancer development with respect to cellular 
growth, differentiation, adhesion, and invasion195. Preclinical studies have demonstrated that 
mucin expression reduces intracellular uptake and response to chemotherapy199. MUC1 and 
MUC2 were originally used by Kitarmura and colleagues200 and Matsubayashi and 
colleagues188 to discriminate between intestinal- and pancreatobiliary-type ampullary 
carcinomas. MUC4 has been found to be overexpressed in ductal pancreatic carcinoma201-205 
and extrahepatic bile duct carcinoma206,207. Due to low expression of MUC4 in the 
normal208-210 and cancerous intestine211, MUC4 might also be used to differentiate between 
pancreatic, biliary, duodenal, and ampullary pancreatobiliary-type versus intestinal-type 
adenocarcinomas189.  
  
 22
Notes on terminology 
Periampullary adenocarcinoma: a subtype of ampullary adenocarcinomas? 
The term “periampullary”* is used in an inconsistent manner in the medical literature213. 
Many authors use the term pragmatically to denominate a primary adenocarcinoma that may 
be removed by pancreatoduodenectomy, irrespective of whether the cancer originated in the 
pancreas, distal bile duct, ampulla or duodenum214. This may seem reasonable due to the 
aforementioned difficulties in determination of the true cancer origin for these tumours. 
However, other investigators restrict the use of this term to denominate the area directly 
surrounding the ampulla, for example in the sense “periampullary duodenal carcinomas”, 
which is thus a duodenal tumour located close to the ampulla31. However, ampullary 
tumours are sometimes subclassified as “intra-ampullary” and “peri-ampullary” carcinomas, 
although the latter may be impossible to distinguish from periampullary duodenal 
carcinomas31. In some research articles, it may seem unclear whether periampullary 
adenocarcinoma refers to a subgroup of ampullary or duodenal adenocarcinomas (or 
both)215. Occasionally, investigators exclude duodenal adenocarcinomas from reports on 
pancreatoduodenectomies without accounting for the possible difficulties in discrimination 
between periampullary ampullary and periampullary duodenal tumours128. 
The disagreement on terminology, and inconsistencies in classification and 
reporting, may cause considerable confusion and adds to difficulties in comparison between 
pancreatoduodenectomy series. For example, peri-ampullary (intestinal-type) ampullary 
tumours might have been excluded from reports on pancreatoduodenectomies for 
adenocarcinomas if the intention was to exclude (periampullary) duodenal tumours. On the 
other hand, pancreatobiliary-type ampullary tumours may have been misdiagnosed as 
pancreatic or biliary tumours. Thus, reports on pancreatoduodenectomy series must include 
tumours of all four origins, as well a clear description of the method used to determine the 
tumour origin and the histologic type of differentiation (pancreatobiliary-type, intestinal-
type, or other histologic type). Importantly, if studies use different methods to classify 
tumours by origin and histologic type (i.e. studies have different sensitivity and specificity 
for diagnosing for example pancreatic versus periampullary tumours), survival statistics 
might be biased in a similar way as commonly referred to as the Will Rogers phenomenon 
(i.e. changes in diagnostic techniques mislead survival statistics due to stage migration216). 
                                                 
* Periampullary, around an ampulla (Dorland's Medical Dictionary for Health Consumers)212. 
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Such an error was simulated on the data obtained at the study hospital (1998-2004) 
to see the effect on median survival for ampullary and pancreatic carcinomas if 
periampullary duodenal carcinomas would have been misclassified as periampullary 
ampullary carcinomas, and if at the same time pancreatobiliary-type ampullary carcinomas 
would have been misclassified as pancreatic carcinomas. Since duodenal and intestinal-type 
ampullary carcinomas have similar prognosis, the “erroneous” inclusion of duodenal 
tumours among ampullary carcinomas had a substantial effect on the estimated median 
survival for ampullary carcinomas (increased from 65 months to 94 months upon 
misclassification). Furthermore, the estimated median survival for pancreatic carcinomas 
was almost unchanged (increased slightly from 15.0 to 15.1 months), due to the fact that 
pancreatic adenocarcinomas and pancreatobiliary-type ampullary adenocarcinomas have 
similar median survival (i.e., 15.2 versus 16.7 months, respectively, confirming the original 
data presented in paper III, figure 4A).  
 
Figure 7. Effect of misdiagnosis on subgroup survival analysis for node-free (N0) versus node-
involved (N1) resections. Survival curves to the right simulate erroneous inclusion of 
pancreatobiliary-type ampullary tumours among resected pancreatic tumours (study hospital, 1998-
2004). Estimated median survival increased from 18 to 24 months for N1 resected patients, and 
decreased from 14 to 12 months for N0 resected patients, when pancreatobiliary-type ampullary 
tumours were “erroneously” included. 
However, the insignificant increase in estimated median survival seen among 
pancreatic cancers by introducing this error was reflected in a much higher effect in 
subgroup analysis, analogous to the Will Rogers phenomenon (Figure 7). In particular, 
estimated median survival for N0 resected patients increased erroneously by 50% (from 18 
to 24 months) due to misclassification with respect to ampullary or pancreatic origin. 
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The inconsistencies regarding the term “periampullary adenocarcinoma” evoked 
many discussions among authors and reviewers of the papers included in the present thesis. 
In the papers I and III, we defined “periampullary” in the pragmatic sense, i.e. including all 
(four origins of) adenocarcinomas potentially resectable by pancreatoduodenectomy. Due to 
the controversies and criticism expressed by several co-authors and reviewers, the use of 
“periampullary” was largely avoided in the papers II and IV. 
Ampulla or papilla – of Vater, Santorini, or Bidloo? 
Petros Mirilas and colleagues69 reviewed the origin of the terms “ampulla”, “papilla”, 
“ampulla of Vater”, and “papilla of Vater” in an article about “benign anatomical mistakes”. 
According to Mirilas, citing the canonical work on “The origin of medical terms” by Henry 
Alan Skinner217: “In anatomy, the term ampulla is applied to a dilated part of a duct or other 
channel.” Dr William S. Haubrich218 stated that an “ampulla is known to us as a small, 
sealed glass container used to preserve medicines in a sterile, stable condition. The word 
comes from Latin ampulla, ‘flask’. ... Interestingly, the Latin ampulla also means bombast 
or inflated discourse, as a ‘blowing out.’ Glass flasks were and are fashioned by blown air.” 
Papilla, according to Mirilas (citing Skinner), “comes from Latin, meaning a nipple or teat, 
and is probably a variant of papula, meaning a small swelling, and is related to papare, 
meaning to suck or feed in an infantile manner.” The hepatopancreatic ampulla should 
therefore, according to Mirilas, refer to “the dilation at the confluence of the bile and main 
pancreatic ducts”, while the major duodenal papilla should refer to the nipple-like opening 
of this structure as seen from the duodenum. 
 In English literature, the term “hepatopancreatic ampulla” is not commonly used. 
The eponymous term “ampulla of Vater” is usually preferred, although according to Mirilas, 
the anatomists Vesalius (1543) and Collins (1685) made account of this structure before 
Abraham Vater (1720)69. Moreover, the structure that Vater described was in fact not an 
ampulla, but an elevation of the mucosa representing what is now denominated the 
perivaterian diverticula69. According to Mirilas (citing Velasco Suárez219), “all the 
anatomists referred to the confluence of the two ducts as a simple union” until Santorini, the 
same year Vater made his discoveries (1720), gave a very precise description of the 
vesicular dilatation that characterises the hepatopancreatic ampulla. Thus, although 
“ampulla of Vater” is still widely accepted in the English literature, this term is wrong and 
should be abandoned in favour of the official anatomic term “biliaropancreatic ampulla” or, 
more simply, “hepatopancreatic ampulla”69. Adding to the confusion, the term “papilla” is 
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often mistakenly used in the medical literature when “ampulla” is meant, and likewise, 
“ampulla” is sometimes used when “papilla” is meant69. Mirilas and colleagues conclude 
that the eponymous term “papilla of Vater” is wrong even when used in the correct context, 
since “it was Gottfried Bidloo who first noted the structure in 1685” 69. Due to frequent 
anatomical misattribution and controversy, other approaches than the continued use of 
eponyms should be considered to honour those pioneers of pancreatic, ampullary, and 
periampullary anatomy68,69,219 and surgery77,220. 
Pancreatobiliary or pancreaticobiliary? 
The most common and “typical” histologic type of adenocarcinoma originating from the 
exocrine pancreatic tissue is the ductal type referred to as the pancreato-
biliary30,31,156,165,191,192,221-228 or pancreaticobiliary 155,156,178,188,224,229-234 histologic type. 
Early investigators such as Kimura and Matsubayashi both denoted this histologic 
type ”pancreat-ico-biliary”155,188, while others such as Albores-Saavedra have used the term 
”pancreat-o-biliary”, for example in the authoritative Atlas of Tumour Pathology31. 
Fingerhut75 argued that pancreatico- should be used when referring specifically to the 
pancreatic duct and pancreato- when referring to the gland in general. Thus, a tumour 
classified according to the histologic type of differentiation as pancreaticobiliary should 
have histological features resembling pancreatic ducts, possibly indicating a ductal 
pancreatic origin. As already mentioned, the tissue of origin (pancreas, ampulla, distal bile 
duct, duodenum, see Box 1) may be intriguingly difficult to determine. However, 
determination of the true cell of origin may be even more difficult, since ductal pancreatic 
carcinomas may also originate from acinar (or endocrine) cells that have undergone 
metaplasia (or transdifferentiation) to a ductal cell form235-237. Furthermore, recent evidence 
points at the possibility that pancreatic cancer may arise from cancer stem cells238-243, which 
may be one reason why these tumours are so resistant to chemo- and radiotherapy244-246. As 
we have shown30,189, the histological phenotype (with or without immunohistochemical 
characterisation of the tumour) may independently predict survival after 
pancreatoduodenectomy for adenocarcinoma. Since such phenotypic classification does not 
rely on determination of the initial cell of origin, we believe that the preferred term should 
be pancreatobiliary histologic type, indicating an origin pertaining to the pancreas, but 
without restricting the definition to tumours originating from pancreatic duct cells. 
However, both terms, pancreatobiliary and pancreaticobiliary, are used synonymously and 
interchangeably in the literature, with few or no practical consequences. 
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Pancreatoduodenectomy or pancreaticoduodenectomy? 
The terms pancreatico-duodenectomy and pancreato-duodenectomy refer to the same 
surgical procedure, i.e. the Whipple procedure in either of its variants (for example classical, 
extended, pylorus-preserving, etc.). As mentioned in the previous section, the strict meaning 
of pancreatico- is somewhat different from the meaning of pancreato-. The removal of 
pancreatic tissue is certainly not restricted to excision of the pancreatic ducts, and the term 
pancreatoduodenectomy should thus be the preferred term75. However, the inaccurate use of 
pancreaticoduodenectomy is of trivial importance, since these terms are used 
interchangeably, with few practical consequences. 
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Aims 
Using a standardised, systematic protocol for histopathologic evaluation and reporting after 
pancreatoduodenectomy for adenocarcinomas in the pancreatic head, ampulla of Vater, 
distal bile duct and peri-Vaterian duodenum, the aim of this thesis was to answer the 
following specific questions with respect to curative-intent resections for such tumours: 
 
1. How often is the retroperitoneal margin involved in non-curative resections? Is resection 
margin involvement, and retroperitoneal margin involvement in particular, an 
independent prognostic factor after curative-intent pancreatoduodenectomy? 
 
2. What is the relative importance of standardised histopathology and institutional volume 
for completeness of histopathologic reporting and accuracy of survival estimates? 
 
3. What is the interobserver variability in classification of the cancer origin of 
pancreatoduodenectomy specimens? May classification by the histologic type of 
differentiation, pancreatobiliary versus intestinal, be used as an adjunct to classification 
of these tumours by their assumed anatomic origin? 
 
4. Does immunostaining for molecular markers of the histologic type of differentiation 
improve classification of the histologic type? May such markers identify patients with 
particularly poor prognosis after pancreatoduodenectomy for adenocarcinoma? 
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Summary of results 
Paper I 
Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection 
margin is an independent prognostic factor.  
BMC Cancer. 2008;8:5. 
 
This paper describes the standardised protocol for histopathologic assessment of the 
pancreatoduodenectomy specimen. The study confirmed that the retroperitoneal resection 
margin, a margin previously often not evaluated in reports from pancreatoduodenectomy 
series, is the margin most often involved in microscopically non-curative resections for 
adenocarcinomas. Furthermore, we found that the retroperitoneal margin is an independent 
prognostic factor after pancreatoduodenectomy for adenocarcinoma. The study also focused 
on the difficulties in determination of the tumour origin (pancreas, distal bile duct, ampulla, 
or periampullary duodenum), and described how the tumour origin might be adequately 
evaluated. Evaluating resection margins and tumour origin by our standardised protocol for 
evaluation of pancreatoduodenectomy specimens, we found that obtaining a free margin had 
significantly less impact on survival after resection of pancreatic tumours than after 
resection of ampullary tumours. In a subgroup analysis of curative (R0) resections, tumour 
origin was found to be the only histopathologic factor independently associated with long-
term survival. However, the sample size was rather small in this subgroup analysis, and 
larger studies might demonstrate statistical significance of additional histopathologic tumour 
characteristics besides tumour origin, as the results from the following papers indicate.  
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Paper II 
Are survival predictions reliable? Hospital volume versus standardisation of 
histopathologic reporting for accuracy of survival estimates after 
pancreatoduodenectomy for adenocarcinoma.  
European Journal of Cancer. Epub April 17, 2009. DOI: 10.1016/j.ejca.2009.03.019 
 
In this paper, we evaluated completeness of histopathologic reporting and accuracy of 
prognostic estimates comparing the study hospital with all other Norwegian institutions 
reporting on pancreatoduodenectomies for adenocarcinoma between 1998 and 2004. We 
evaluated the importance of standardised histopathologic evaluation and reporting at the 
study hospital with evaluation at other medium-volume and at low-volume institutions.  
The study demonstrates that standardisation of histopathologic reporting is more 
important than hospital volume for completeness of histopathologic reporting and for 
accuracy of prognostic estimates, particularly with respect to lymph node evaluation. The 
study included all pancreatoduodenectomies reported during this time period to the Cancer 
Registry of Norway, a population-based database that by law receives mandatory reports 
from all Norwegian surgical and pathological institutions. This registry includes information 
about the morphologic and topographic tumour diagnosis (i.e. histologic type and anatomic 
location of tumour origin, respectively), as well as nodal status, and degree of 
differentiation. These prognostic factors were retrieved from the histopathologic reports and 
prospectively registered for all reported pancreatic head adenocarcinoma resections. 
Completeness in reporting of histopathologic prognostic factor was significantly higher in 
reports from the study hospital compared to reports from other institutions of medium or 
low institutional volume. Lymph node status was the histopathologic prognostic factor that 
seemed to depend most on standardisation of histopathologic examination. The number of 
lymph nodes retrieved was significantly higher at the study hospital, and the ability to 
discriminate between favourable (N0) and poor (N1) prognostic groups was significantly 
higher at the study hospital compared to the other institutions. Standardisation of 
histopathologic reporting may be less important for accuracy of prognostic estimates with 
respect to resection margin evaluation, estimation of tumour size, and evaluation of the 
cancer origin.  
 32
Paper III 
Pancreatobiliary versus intestinal histologic type of differentiation is an independent 
prognostic factor in resected periampullary adenocarcinoma.  
BMC Cancer. 2008;8:170. 
 
Although the tumour origin (pancreas, distal bile duct, ampulla, or duodenum) may be 
difficult to determine with certainty, these adenocarcinomas are considered separate entities 
in TNM classification and staging according to the recommendations by WHO, UICC and 
AJCC. However, the pancreas, ampulla of Vater, and distal bile duct are all embryologically 
derived from the duodenum, and each of these tumours may sometimes have 
histopathologic features that make them morphologically indistinguishable from colonic 
adenocarcinomas. Acknowledging this, ampullary tumours have often been subdivided in 
intestinal and pancreatobiliary types, according to their histologic type of differentiation, 
and the intestinal type of ampullary tumours has consistently been shown to be associated 
with more favourable long-term survival. In this study, we hypothesised that the phenotype, 
either intestinal or pancreatobiliary, might thus be more important than the assumed cancer 
origin in terms of tumour biology, and patient prognosis after resection. Among all patients 
who underwent pancreatoduodenectomy at the study hospital between 1998 and 2004, we 
compared determination of the tumour origin with classification of the histologic type, 
pancreatobiliary versus intestinal. For the first time in the medical literature, to our 
knowledge, we presented individual frequencies for each of these two histologic types in a 
series of consecutive pancreatoduodenectomy resections for adenocarcinoma. As expected, 
exceptionally few pancreatic and distal bile duct tumours were intestinal-type, whereas 
approximately two thirds of ampullary tumours and all duodenal tumours were intestinal-
type adenocarcinomas. However, the histologic type was easier to determine and a better 
predictor of survival after curative-intent pancreatoduodenectomy for adenocarcinomas. 
Among tumours with pancreatobiliary-type differentiation, lymph node involvement, vessel 
involvement, and increasing tumour size were independent adverse prognostic factors. The 
main results from this study were validated using resections performed at the study hospital 
1980-1997 as an historical control. 
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Paper IV 
Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 
expression indicates poor prognosis in pancreatobiliary differentiated tumours.  
Histopathology. 2009;54:337-47. 
 
In the fourth study, we investigated whether immunohistochemical characterization using 
molecular markers associated with the histologic type, pancreatobiliary versus intestinal, 
could be useful in classification of these tumours. For the purpose of this study, we included 
pancreatoduodenectomies performed at the study hospital 1980-2004, and evaluated 
immunoreactivity for several molecular markers in archived tissue material. The 
immunohistochemical analyses were performed on small samples of tumours aligned in 
tissue microarrays (TMA), which allows simultaneous evaluation of several molecular 
markers with minimal use of expensive antibodies and valuable tissue material. In this 
study, we found that immunohistochemical characterisation using antibodies directed at 
molecular markers of the histologic type of differentiation, pancreatobiliary versus 
intestinal, did not discriminate better between the two histologic types than classification of 
the tumours after haematoxylin and eosin staining of ordinary sections. Furthermore, such 
immunohistochemical classification of the histologic type did not discriminate better 
between prognostically favourable versus poor subgroups. However, immunostaining with 
MUC1 and MUC4 identified a subgroup of patients with pancreatobiliary-type 
differentiation that had a particularly poor prognosis. The finding might be useful in future 
development of treatments targeting these molecules or signalling pathways in which these 
molecules are involved. 
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Discussion 
Methodological considerations 
The methods have been described and discussed in the included papers. The following is an 
additional overview and reflection on strengths and limitations to the methodology applied.  
Patient selection, follow-up, censoring, and completeness 
The patients included in the present work comprise all patients who underwent 
pancreatoduodenectomy at Rikshospitalet University Hospital (study hospital) between 
1980† and 2004, as well as all patients who underwent pancreatoduodenectomy in Norway 
between 1998 and 2004 identified through histopathology reports to the Cancer Registry of 
Norway (Figure 8).  
 
Figure 8. Patient selection for studies included in the present thesis. 
The number of pancreatoduodenectomies performed at the study hospital per year 
increased steadily from < 10 in the 1980s to 20-40 in the last decade (Figure 9). A 
                                                 
† Registration of patients who underwent pancreatoduodenectomy started during the spring of 1980. There 
may have been a few more pancreatoduodenectomies earlier this year. These few, if any, patients who may 
have undergone resection in 1980 before registration started, have thus not been included in the present work. 
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standardised protocol for histopathologic assessment of the pancreatoduodenectomy 
specimen was implemented at the study hospital in 1998. The study hospital is a tertiary 
referral hospital serving approximately one million inhabitants in the South-Eastern region 
of Norway. There is one other tertiary hospital in the same region, with similar numbers of 
pancreatoduodenectomies per year. Patients are referred from a number of different 
institutions to either one of these two hospitals, depending on the address of each patient, 
with no probable bias on age, gender, social status, previous health record, or tumour 
characteristics. There were no national or regional guidelines for standardisation of 
histopathologic assessment and reporting during the study period. Furthermore, national 
guidelines did not recommend adjuvant treatment as routine practice prior to 2006. 
 
Figure 9. Pancreatoduodenectomies performed at Rikshospitalet University Hospital (study 
hospital), 1980-2004. Total number of resections, 311 (minimum 2, maximum 40). 
For the purpose of papers I, III, and IV, patients were retrieved by prospective 
registration of pancreatoduodenectomies, by review of operation protocols and pathology 
reports, as well as by electronic searches in the patient administrative system at the study 
hospital. A few patients might have been missed early in 1980 since prospective 
registrations of pancreatoduodenectomies started during the spring and not at the beginning 
of the year. However, the number of missed patients is probably less than five. Follow-up 
was complete for all patients except for censoring due to end of the study period. Follow-up 
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was limited to five years, whereas most patients were dead within two years (minimum 
follow-up for survivors, 1.6 years; paper I). Censoring may thus not significantly have 
biased the results of the presented analyses. 
In paper II, all reported pancreatoduodenectomies in Norway between 1998 through 
2004 were identified by a search in the Cancer Registry of Norway, a nationwide, 
population-based database. A strength of this study was that it evaluated population-based 
and nationwide data on resected pancreatic head adenocarcinomas, with high level of 
completeness247, no patients missed to follow-up, and minimum 3.4 years of follow-up time 
for the surviving patients. Thus, few patients were censored, and inclusion bias was reduced 
to an absolute minimum. The patients identified by the search in the Cancer Registry did not 
reveal any missed patients from the original recordings performed at the study hospital. 
However, nine patients that had been identified by the prospective registration, manual 
review, and electronic searches at the study hospital were missed by the applied search 
strategy in the Cancer Registry. The explanation for this is that identification of patients at 
the Cancer Registry was limited to review of pancreatoduodenectomy pathology reports, 
and that some reports had not been sent to the Cancer Registry from the reporting 
institutions. A search in the Cancer Registry to include a review of reports from all biopsy-
proven pancreatic head adenocarcinomas (in addition to the reports from 
pancreatoduodenectomy specimens) would have required review of reports from 4803 
patients‡. This was considered far too extensive, and unnecessary for the purpose of this 
study. Since some reports might also be missing from other hospitals, the missing reports 
from the study hospital were not included. Importantly, we do not believe that the missing 
data may have biased the results in a direction contrary to the conclusions presented in this 
study§. 
Histopathology 
Most of the present work has been accomplished by evaluation of ordinary haematoxylin 
and eosin stained sections, a method developed as early as in the 1870s and perhaps not so 
“modern” although still fundamental to modern surgical pathology248. In an age of advanced 
                                                 
‡ In addition, the Cancer Registry receives clinical reports, and making use of all available information at the 
Cancer Registry would have identified all except one pancreatoduodenectomy at the study hospital.  
§ Missing reports are not likely to have been of superior quality compared to those received at the Cancer 
Registry. In particular, reports missing and received from the study hospital were of similar quality. 
Insufficient logistics, rather than insufficient pathology, is the likely reason for why reports were not received. 
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technology, with a plethora of opportunities in genetics and nanotechnology, the power of 
such a simplistic methodology should be neither over- nor underestimated**. The ability of 
the pathologist to identify on ordinary stains a distinct pattern reflecting the severity and 
underlying biology of the disease is astonishing to a non-pathologist. Furthermore, 
immunohistochemistry is invaluable to characterise morphologic details that may not be 
visible on ordinary stained sections, as well as give a more precise structural, molecular, and 
functional idea of the tumour characteristics.  
Immunohistochemistry 
Immunohistochemical procedures and histopathologic evaluation performed as part of the 
present study were principally carried out by experienced technicians and pathologists at the 
pathology department of the study hospital, in which there are established routines for 
immunohistochemistry (including quality control). The following is therefore only a brief 
description of some important methodological limitations and considerations regarding 
immunohistochemical evaluation of pancreatoduodenectomy specimens249,250.  
Problems in interpretation of immunostains may arise from varying methods for 
tissue fixation over time and between institutions. The present work included evaluation of 
some specimens that were over 25 years old. In ordinary haematoxylin and eosin stained 
sections, aging of the wax blocks does not represent a problem249, whereas for some 
immunohistochemical staining protocols this may be more challenging. Not only aging of 
the waxed specimen itself, but variations in fixation protocols over time (for example in the 
pH of the applied diluent buffer)251, may result in inadequate staining unless antigen 
retrieval and immunostaining protocols are optimised249.  
 Most of the immunohistochemistry in 
the present work was performed on sections 
from tissue microarrays252-256 (Figure 10), 
although immunostains from these arrays were 
also compared with ordinary sections for 
selected tumours. The major strength of tissue microarray technology is that a large amount 
of specimens may be evaluated under the same conditions, since the inevitable variability 
Figure 10. Tissue microarray 
                                                 
** Genetic and preclinical studies are certainly necessary to reveal the true nature and principle mechanisms of 
pancreatic and periampullary cancers, in order to develop effective treatments for patients with these cancers. 
However, application of such techniques was beyond the scope of this thesis. 
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seen when staining individual whole-sections is reduced by applying the exact same 
methodology to all the samples processed on a single microscopic slide. Furthermore, 
reducing the number of slides to be stained, and evaluated, saves time, reduces the amount 
of antibody needed for analyses, and saves invaluable tissue that may then be used for 
further analyses. However, adjustment to varying fixation protocols and age of specimens is 
not so straight-forward in tissue microarrays, in which a large number of tumours that may 
have been subject to different fixation protocols (and storage time), are processed 
simultaneously, without the possibility to adjust antigen retrieval and staining protocols 
individually, as could be necessary. Furthermore, tissue microarrays are composed of small 
biopsy cores from each tumour, and results may be biased by selective sampling if tumour 
markers are heterogeneously expressed. In the present study, such variability due to possible 
heterogeneousness was avoided by use of rather large cores (1.0 and 1.5 mm diameter) and 
by evaluating more than one core from most tumours. 
In general, results obtained by immunohistochemistry must be interpreted in light of 
possible variations in fixation and antigen retrieval techniques, specificity of primary and 
secondary antibodies, differences in use of chromogen detection and signal amplification 
procedures (for example use of, and blocking for, endogenous biotin), adequate use of 
internal controls (which are difficult to quantify), as well as other differences in staining 
protocols (for example time of exposure to antigens)257-261. Furthermore, peptide binding 
sites may be hidden by glycosylation, which represents a particular problem when 
evaluating the mucin proteins studied in the present work. And finally, identification of 
prognostic groups by combined expression and/or absence of several different molecular 
markers might and might not be biologically relevant.  
Although the adequate threshold to define a true positive sample relies on 
methodology (for example antigen retrieval249) which in addition to disease prevalence may 
vary from one dataset/institution to another, optimisation of cut-points to maximise the 
difference between “positive” and “negative” samples  increases the risk of reporting 
significant results by chance262. The same risk applies to optimising the combination of 
markers used to define a “positive” sample, unless such optimisation is used to prove that no 
“optimal” combination is in fact an adequate discriminator between positive and negative 
samples189. Efforts to standardise reporting on prognostic markers250,263-265 have proven 
difficult to implement in practice266. Selective publication of positive results also adds to the 
concerns about the discriminating ability of reported prognostic markers267. Reports on 
tumour markers thus need confirmation by use of different methodological approaches and 
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by validation in separate datasets before applying results in clinical studies. Although a 
powerful tool to see structural and physiological characteristics and generate new 
hypotheses, the ultimately qualitative nature of immunohistochemistry (although some 
quantification methods do exist) must be recognised and acknowledged. 
In the present work (paper IV), each of the issues mentioned above were considered 
separately for each antibody, in addition to routine quality control performed at our 
institution (including testing of antibody specificity by Western blotting). Furthermore, for 
selected stains we tested interobserver variability with respect to scoring of the stained 
specimens. However, we did not validate the results from immunohistochemistry using 
alternative methodology (for example genetic or in situ hybridisation studies), nor validate 
the results in separate datasets. These results thus need validation in separate studies. 
Standardised histopathologic evaluation, synoptic reporting 
Standardisation of histopathologic reporting is important to avoid bias and make results 
applicable to clinical guidelines29. Prospective registration of important histopathologic 
prognostic factors should thus be standardised between pathologists, between institutions, 
and between continents268,269. In particular, protocols should be standardised between 
institutions in order to improve multi-centre comparisons28. There have been numerous 
suggestions for standardisation of histopathological evaluation and synoptic reporting of 
pancreatoduodenectomy specimens23,24,33,161,270-280. Substantial improvement of the quality 
of histopathologic reporting for pancreatic, biliary, ampullary, and duodenal 
adenocarcinomas may be achieved (1) by standardising macroscopic evaluation, 
preparation, and sectioning, (2) by standardising microscopic evaluation, and (3) by use of 
template-based, synoptic reporting of pancreatoduodenectomy specimens. The various 
published protocols on histopathologic evaluation and reporting are, however, 
inconsistent23,136.  
Resection margin involvement 
Retroperitoneal resection margin – varying definitions 
In the present work, we defined the “retroperitoneal margin” as “the area of sharp dissection 
in the peripancreatic fatty tissue behind the pancreatic head and lateral to the mesenteric 
vessels” (paper I). A resection margin is a margin of sharp surgical dissection††217,281,282. 
                                                 
†† Skinner217: “Resection (latin resectio), a cutting off or trimming, from resecare, to cut loose, or cut off.” 
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The posterior and medial peripancreatic soft tissue margins (posterior to the pancreatic head 
and medial to the uncinate process adjacent to the superior mesenteric artery, with some 
peripancreatic tissue lying in between283) is referred to by different names in the scientific 
literature136,283,284. In the lack of international consensus on terminology, we chose to use the 
term “retroperitoneal resection margin” because it was the term most frequently used at the 
time the present work was initiated. However, some authors23,284 consider “retroperitoneal 
margin” a misnomer due to the fact that the entire pancreatic head, not only the posterior 
aspect, is located retroperitoneally. Moreover, the evaluated “retroperitoneal margin” may 
not be the same in reports from different centres11,136,283-285, or from different pathologists. 
In the present work, we have extended the definition of the “retroperitoneal margin” applied 
in for example the AJCC Cancer Staging Manual33, by including a wider area representing 
the peripancreatic posterior (surgical) dissection margin, as described in more detail in paper 
I (see figure 1, paper I). Some investigators have advocated examination of the entire 
“circumferential resection margin”24,128,286. The anterior surface of the circumferential 
margin is in fact not a resection margin287, and although it does make sense to determine the 
distance of tumour growth relative to the entire surface of the excised surgical specimen23, 
we did not routinely examine the anterior margin in the present work. However, the 
retroperitoneal resection margin is the margin most often involved in R1 resections, and this 
margin is often simultaneously involved in cases where tumour invasion is seen at other 
margins24,128,129,133,134,136,288. 
Residual tumour (R) classification 
Residual tumour classification was incorporated into the fourth edition of the TNM 
Classification of Malignant Tumors in 1978 and in the corresponding third edition of the 
AJCC Manual for Staging of Cancer (see detailed description of the current R classification 
in the TNM Supplement289). According to the last edition of the staging manual33, the 
following margins should be routinely evaluated in pancreatoduodenectomy specimens: 
“common bile (hepatic) duct, pancreatic neck, retroperitoneal margin, other soft tissue 
margins (such as posterior pancreatic), duodenum, stomach”. In addition, the anterior 
serosal surface of the pancreatic head is sometimes considered a “resection margin”24,128,277, 
although this surface is not actually a surgical margin23,290. As mentioned above, there is 
considerable variation between studies with respect to evaluation of the resection margins, 
and this may be one reason for the wide range of reported R1 rates in different studies  
(Table 1)23. 
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Moreover, differences in reported R1 and R0 rates between studies may be explained by 
variations in 
 marking and inking of resection margins 
 determination of the tumour origin (eg., the rates of ampullary versus pancreatic 
adenocarcinomas varies considerably between studies, which may be attributed to 
misdiagnosis rather than real differences in the relative incidences for these 
tumours)25 
 method of sectioning of resection margins; some evaluate the retroperitoneal margin 
by a single “shave section” (parallel to the resection margin), whereas others 
evaluate serial sections perpendicular to the resection margin 
 number of sections evaluated from each resection margin 
In the current version of TNM residual tumour classification291, R1 is defined as tumour 
involvement at any of the resection margins (clearance 0 mm), whereas R0 is defined as 
tumour clearance at any distance (> 0 mm) from the resection margins. However, pancreatic 
adenocarcinomas may spread in the form of isolated ducts and cells situated in the midst of 
normal pancreatic tissue or in peripancreatic fat and connective tissue143,292. Thus, some 
investigators have defined an R0 resection as tumour clearance > 1 mm, and 
correspondingly, defined an R1 resection as tumour involvement within 1 mm from the 
resection margins24,128,272. Some investigators have suggested that a tumour clearance more 
than 1 mm (eg. 1.5 mm) could even be more appropriate to define a curative resection134,285. 
However, most articles on pancreatoduodenectomies for adenocarcinoma do not state the 
exact distance used to discriminate a margin-free versus a margin-involved resection, a fact 
that adds difficulties to comparisons between series. 
Wittekind and colleagues recently proposed to expand the R classification293, in an 
attempt to eliminate confusion (with particular focus on differences in definitions for R 
classification and circumferential resection margin involvement in colorectal cancer, but 
suggesting that the same classification should be used for other cancers, including 
pancreatic head carcinomas). According to this revision293, R1 should now be defined as 
tumour clearance > 1 mm from the resection margins. Figure 11 summarises the current 
criteria for R classification encompassing this revision. 
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Microscopic evaluation of 
the resected specimen
Gross evaluation (pre- and 
intraoperative evaluation)
Residual distant metastasis or 
loco-regional tumour?
No: R0/R1
R0: No residual tumour, clearance
to resection margins > 1 mm
R1:Tumour clearance  1 mm
from resection margin
R1-dir: Microscopic residual
tumour  at resection margin
Yes: R2
R2a: Local macroscopic residual 
tumour
R2b: Distant macroscopic residual
tumour
R2c: Local and distant
macroscopic residual tumour
 
Figure 11. Expanded residual tumour (R) classification (adapted from TNM Supplement, 2003, 
and Wittekind and colleagues, 2009)289,293 
Some points of note289,291,293: 
 In R classification, both local-regional residual tumour and distant residual tumour 
(remaining distant metastases) should be taken into consideration. 
 Cases with distant metastases (M1) that (in addition to the primary tumour) have 
been removed completely are thus classified as R0. 
 Cases should be classified as RX if the pathologist cannot make a reliable 
topographical orientation and assessment of the resection lines, for example if the 
tumour is removed in two or more parts (not en bloc). 
 R classification corresponds to detectable residual tumour, and R0 does not 
necessarily represent a curative resection. 
 According to the TNM Supplement recommendations, a carcinoma in situ lesion at 
the resection margin (i.e. PanIN3) should be classified as R1 with the suffix “is”, i.e. 
R1(is). However, there is no uniform agreement, and such lesions are sometimes 
classified as R011. Data on the clinical importance of PanIN3 at the resection 
margins is scarce144. In the present work, there were only a few cases with PanIN3 at 
the resection margins, and these were classified as R0.  
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Statistical considerations 
Sample size, heterogeneity; stratification or multivariable analysis 
Papers I, III, and IV evaluate prognostic factors for overall survival among 114 consecutive 
pancreatoduodenectomies for 40 pancreatic, 41 ampullary, 17 distal bile duct, and 16 
duodenal adenocarcinomas. Tumours of separate origins may be heterogeneous with respect 
to histopathologic and biologic characteristics32. The number of patients evaluated in the 
present work was limited, for each of the separate tumour origins. However, due to the 
aforementioned inherent difficulties in distinguishing between pancreatic head tumours of 
separate origins, tumours of all four origins were included in a multivariable Cox regression 
analysis, in which these differences can be adjusted for adequately with respect to their 
association with overall survival. The feasibility of this analysis was evaluated by 
examination of log minus log plots. Furthermore, we proposed that this should be the 
preferred method for reporting on prognostic factors after pancreatoduodenectomy, rather 
than only presenting the results from separate subgroups, since these subtypes with respect 
to tumour origin may not be clearly distinguishable. 
The primary outcome variable in all four studies included in the present work was 
death from any cause; i.e., we studied overall and not disease-specific survival 
(discriminating between perioperative death and conditioned long-term survival). Most 
patients who undergo curative-intent pancreatoduodenectomy for adenocarcinoma die from 
recurrence of this disease within few years130. Accordingly, median survival was only 1-2 
years in each of the four studies in this thesis, similar to other studies (Table 1). We 
therefore believe that evaluation of disease-specific death would not have altered the 
conclusions substantially and was thus not necessary in the current context. 
 In paper II, we compared institutions with different protocols and standards for 
histopathologic evaluation and reporting. The study hospital was compared with other 
medium-volume institutions and with low-volume institutions. The actual numbers of 
pancreatoduodenectomies for adenocarcinoma performed at the study hospital and at the 
three medium-volume institutions were 113 (study hospital), and 94, 80, and 47 (medium-
volume institutions), respectively. The medium-volume institution with least volume 
performed less than half the number of pancreatoduodenectomies compared to the study 
hospital. However, inclusion of only two hospitals in the medium-volume category would 
increase the possibility of obtaining differences by chance. The mean number of operations 
at the 21 low-volume institutions was much lower than the number of 
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pancreatoduodenectomies performed by the medium-volume institution with the lowest 
volume (8.2 versus 47). Thus, we considered the comparisons appropriate with respect to 
hospital volume. However, it should be recognised that the study hospital not only differed 
from the other medium-volume institutions in terms of standardisation of histopathologic 
evaluation and reporting, but also in terms of volume of surgery (and pathology). 
 The cutpoints defining “high-volume” and “medium-volume” institutions in 
pancreatic surgery vary considerably in the published literature121. In general, the number of 
patients in “high-volume” centres is considerably lower for pancreatoduodenectomies than 
for operative procedures in for example heart or vascular surgery109,294. The threshold for a 
possible improvement on survival estimates due to increasing hospital or surgeon volume 
may be higher than the cutpoint of 47 resections per 7 years (~7 resections per year) set in 
the present study. Furthermore, volume of surgery is not entirely the same as volume of 
pathology, which we did not measure in our study. However, the main conclusion in this 
paper was that prognostic accuracy for lymph node evaluation depended more on 
standardisation of histopathology than on volume of surgery. To evaluate whether the 
threshold for obtaining an effect of institutional volume on accuracy of histopathologic 
reporting could have been set too low, we also compared the three medium-volume 
institutions with respect to prognostic validity for lymph node staging (data not published, 
for confidentiality reasons). Among these three medium-volume institutions other than the 
study hospital (mean number of pancreatoduodenectomies for adenocarcinoma per year: 13, 
11, and 7, respectively, compared to 16 at the study hospital), there was no indication that 
the institution with the highest work-load had more accurate survival estimates based on 
lymph node evaluation. In fact (by coincidence), we found a trend indicating that the 
medium-volume hospital with the lowest workload had the highest hazard ratio for lymph 
node involvement, although non-significant. Thus, long-term survival could not be predicted 
more accurately at institutions with higher workload based on lymph node evaluation in the 
present study. However, although our data indicate that standardisation of histopathologic 
evaluation and reporting is more important than institutional volume, we cannot rule out that 
an effect of increasing workload on quality of histopathology, irrespective of measures to 
standardise histopathologic reporting, might be seen at institutions with even higher work-
load than those evaluated in this study. 
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Validity, accuracy, completeness, correctness 
We believe that the main conclusions drawn from the four included papers are valid, i.e. that 
the conclusions are likely to be true in view of the measures used and in the applied research 
design (internal validity)29,295. For example, statistical tests and predefined cut-off levels to 
define positive immunostaining were chosen in order to avoid inflation of arbitrary (false 
positive) results. External validity must be confirmed by independent studies, i.e. studies 
that apply the same methods on a separate sample of subjects. However, some further 
validation was also performed in the present work, particularly in paper III. 
In this paper (paper III), we validated the results from our study on an historical 
control cohort from the same institution. Results from historical cohorts may inevitably be 
biased by changes in treatment practice over time, as well as by changes in for example 
methods for processing pathology specimens. In spite of these limitations, evaluation with 
an historical control group may provide additional proof of concept, and confirm or 
contradict results from the main study analysis. We believe that evaluation of the results 
from the main analysis using an historical control group in paper III adds strength to the 
conclusions drawn in this study, although we acknowledge the limitations of this approach. 
The results from this study, as well as the other three studies, should thus be evaluated in 
independent studies. Importantly, external validity should be established before applying the 
results to clinical studies28.  
The use of terms such as validity, as explained above, as well as completeness, 
accuracy, adequacy, and quality may sometimes be confusing. The following is a brief 
discussion on these and related terms in the context of paper II. Accuracy is the degree of 
closeness of a measured or calculated quantity to its actual (true) value. Based on previous 
studies and our own experience, we assumed that standardised (evaluation and) reporting 
may improve the level of details (completeness), which in turn might affect the diagnostic 
accuracy. The results from our study do indicate that diagnostic accuracy may improve, 
although we did not evaluate diagnostic accuracy in particular. For example, with respect to 
tumour origin classification, non-standardised reporting led to significant underreporting of 
ampullary and duodenal tumours. We hypothesised that completeness of histopathologic 
reporting might in turn be important for accuracy of prognostic estimates (i.e. prognostic 
accuracy, or prognostic validity). Analogous to our approach for evaluation of the 
prognostic accuracy in paper II, Tomlinson and colleagues296 evaluated “accuracy of staging 
node-negative pancreas cancer” by determining the minimum number of lymph nodes 
required to optimally discriminate between prognostic favourable versus prognostic poor 
 46
groups. However, Tomlinson and colleagues only evaluated the prognostic accuracy for 
lymph node staging, whereas paper II compares the effect on survival estimates for each 
reported histopathologic factor independently, in a setting of standardised versus non-
standardised histopathology reporting. Finally, since the purpose of histopathologic 
reporting is to provide information about the patient prognosis after resection, we conclude 
in paper II that standardised reporting increases quality or in fact adequacy of 
histopathologic reporting, as stated in the article. 
Discussion of results 
This thesis evaluates the importance of standardising histopathologic assessment and 
reporting after pancreatoduodenectomy for adenocarcinomas in the pancreatic head, distal 
bile duct, ampulla of Vater, and peri-Vaterian duodenum. The included papers focus 
particularly on the importance of standardised evaluation of the resection margins and 
tumour origin, on histopathological and immunohistochemical classification of the 
histologic type versus the tumour origin, and on the importance of standardised reporting for 
accuracy of prognostic estimates. Most patients who are diagnosed with an adenocarcinoma 
in the pancreatic head die within few months after diagnosis1,2,5,21. Even when the tumour is 
surgically resectable, complete removal of a typical ductal pancreatic adenocarcinoma offers 
only approximately 1-2 years of prolonged survival (Table 1). The effect of adjuvant 
treatment is limited, and new treatments are urgently needed3,15,297. Standardised evaluation 
of resected specimens should be an important measure to avoid bias in clinical 
studies17,28,29,250. However, histopathologic assessment and reporting of the 
pancreatoduodenectomy specimen is often non-standardised23,25. In particular, clinical 
studies might fail to prove new treatments effective if determination of resection margin or 
lymph node involvement is insufficient17,26-28, or if tumour types that respond dissimilarly to 
the offered treatments should be included simultaneously, inadvertently, in such 
studies32,35,86.  
Taken together, the four papers included in the present thesis demonstrate that 
standardised histopathologic assessment after pancreatoduodenectomy for pancreatic, 
ampullary, distal bile duct, and duodenal adenocarcinomas is necessary for complete, 
consistent, and correct classification of tumours and for reliability of prognostic estimates. 
Standardisation of histopathologic evaluation and reporting was found to be more important 
than institutional volume, and standardisation of lymph node evaluation was particularly 
important to discriminate adequately between favourable versus poor prognostic groups. 
 47
Non-curative resection is most often due to involvement of the retroperitoneal margin. 
Discrimination between curative (R0) and non-curative (R1) resections had a larger impact 
on long-term survival for ampullary than for pancreatic carcinomas. Although the tumour 
origin (pancreas, distal bile duct, ampulla, or duodenum) was an independent prognostic 
factor in curative (R0) resections, accurate determination of the tumour origin may be 
impossible in some cases, and the histologic type of differentiation, pancreatobiliary versus 
intestinal, was a better prognostic indicator than the tumour origin. In multivariable survival 
analysis, the histologic type of differentiation (pancreatobiliary versus intestinal) was the 
strongest adverse predictor of survival (hazard ratio 3.1, 95% confidence interval [1.8-5.1]), 
followed by lymph node involvement (hazard ratio 2.5, 95% confidence interval [1.5-4.4]). 
In pancreatobiliary-type adenocarcinomas of comparable size, survival did not differ 
for patients depending on whether the tumour originated from the pancreas, ampulla, or 
distal bile duct. Furthermore, nodal involvement, vessel involvement, and increasing tumour 
size were independent adverse prognostic factors. The histologic type of differentiation may 
be determined with almost perfect agreement between two independent observers, and 
tumours with mixed-type differentiation may be classified by the most prominent histologic 
type. Immunohistochemical characterisation targeting markers of the histologic type of 
differentiation (including cytokeratins, mucin proteins, and the homeodomain protein 
CDX2) is often used as evidence of the line of differentiation, although such 
immunohistochemical characterisation only partly corresponds to subclassification 
(pancreatobiliary versus intestinal) using ordinary haematoxylin and eosin stained sections. 
Immunohistochemical subclassification of tumours did not discriminate better between 
prognostically poor versus favourable subgroups of patients than subclassification based on 
evaluation of ordinary haematoxylin and eosin stained sections. However, immunostaining 
directed at identification of MUC1 and MUC4 may be used to identify patients with 
particularly poor prognosis among those who have pancreatobiliary-type tumours. 
The systematic protocol for standardised evaluation and reporting of histopathologic 
prognostic factors described in papers I and II differs in some respects from recently 
published protocols and recommendations23,24,277,279. However, the most important issue 
should be to reach international consensus on a single recommendation, and to implement 
the use of standardised protocols worldwide. We have focused particularly on the 
importance of tumour involvement of the retroperitoneal resection margin, a margin often 
not evaluated in reports on pancreatoduodenectomy specimens, and on determination of the 
precise tumour origin (pancreatic, biliary, ampullary, or duodenal). The retroperitoneal 
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margin was the margin that was most often involved in incomplete resections. This has also 
been shown previously128,288, and confirmed in later studies24,129,133,134,215. We found that 
retroperitoneal margin involvement was an independent adverse prognostic factor after 
curative-intent pancreatoduodenectomy for adenocarcinoma. However, the benefit of a 
margin-free resection was significantly more pronounced for patients with ampullary 
tumours compared to patients with pancreatic tumours. 
In paper II, we reviewed histopathologic reports from all 25 Norwegian institutions 
that performed pancreatoduodenectomies in the period 1998-2004. We found that 
standardised histopathologic evaluation was more important than surgical volume for 
completeness of histopathologic reporting. Other studies have shown that standardised 
reporting may improve detection of poor prognostic factors in various cancers (e.g., for 
estimating the true frequency of lymph node involvement in pancreatic adenocarcinomas296, 
as described in the “Statistical considerations” section). However, no previous study has to 
our knowledge investigated whether standardisation actually increases accuracy of 
prognostic estimates using all available information from the pathology reports. 
Furthermore, we found that lymph node involvement was the factor that was most 
dependent on standardised reporting to discriminate between favourable and poor 
prognostic subgroups. Lymph node evaluation has many times previously been recognised 
as an important histopathologic prognostic factor, particularly when more than one positive 
lymph node is detected132,298-304. The total number of evaluated lymph nodes has been 
suggested as an indicator of the quality of histopathologic reporting296,302,305-309. However, 
the total number of lymph nodes extracted during pancreatoduodenectomy (and evaluable 
for the pathologist) may vary considerably even for a single surgeon. 
In paper III, we compared classification of pancreatoduodenectomy specimens by 
tumour origin (pancreatic, biliary, ampullary, or duodenal) with classification according to 
the histologic type of differentiation (pancreatobiliary versus intestinal). As detailed in the 
introduction of this thesis, failure to reach a correct diagnosis of the cancer origin (which 
may be impossible to determine in some instances31,70,153,159,161) may lead to false 
assumptions regarding long-term survival25,30-32. Misclassification of the tumour origin has 
been reported in up to 39% of long-term survivors62. Comparing the original histopathologic 
reports on pancreatoduodenectomy specimens with an independent reevaluation of the 
microscopic slides, we found that interobserver agreement in classification of the cancer 
origin was only fair to moderate (kappa=0.37; 95% CI=[0.25, 0.49]), whereas agreement 
was significantly better (kappa=0.68; 95% CI=[0.57, 0.79]) when the reevaluation also 
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included review of the operative and macroscopic reports. Determination of the probable 
anatomic tumour origin thus requires careful consideration of clinical, surgical, and 
macroscopic characteristics, as well as appropriate histopathologic specimen dissection and 
adequate preparation of microscopic slides (papers I and III). In particular, a whole mount 
section parallel to the biliary tract, ampulla of Vater, and main pancreatic duct, and also 
including the peri-Vaterian duodenum, should be obtained in order to demonstrate the 
tumour’s relation to each of these structures of potential origin (paper I).  
Staging according to the TNM criteria relies on a correct diagnosis of the cancer 
origin, since staging criteria are different for the separate origins33,34. The World Health 
Organization’s recommendations for classification of these tumours35 also includes 
classification according to a morphologic diagnosis, i.e. the histologic type. In particular, 
ampullary tumours may easily be misclassified as duodenal or pancreatic/biliary tumours. 
Even in cases when the ampullary tumour is easy to determine, eg., small infiltrating 
carcinomas with an associated intraampullary component and prominent dysplasia of the 
ampullary epithelium adjacent to the neoplastic tissue, ampullary tumours may have either 
intestinal-type or pancreatobiliary-type differentiation. Thus, we hypothesised that 
classification by the histologic type of differentiation for all four periampullary origins 
could be more relevant with respect to estimating long-term survival after curative-intent 
pancreatoduodenectomy for adenocarcinomas. This has not been evaluated previously. 
There have been some previous reports on intestinal-type pancreatic and biliary tract 
carcinomas, although not in a context of consecutive reporting for a 
pancreatoduodenectomy series. This study confirms the previous assumption that intestinal-
type pancreatic (and biliary tract) carcinomas are rare, although Albores-Saavedra and 
colleagues148 reported that intestinal-type adenocarcinomas might be more frequent than 
previously believed – according to them, this entity may represent the second-most frequent 
histologic subtype of ductal pancreatic carcinomas (the typical pancreatobiliary-type 
carcinomas being the most frequent subtype). However, larger studies must establish the 
true incidence of these tumours in pancreatic and distal bile duct carcinomas. Importantly, 
the finding that evaluation of the histologic type of differentiation, pancreatobiliary versus 
intestinal, was a better predictor of survival than the anatomic tumour origin after 
pancreatoduodenectomy raises the question whether we really need a separate classification 
for ampullary carcinomas162. In accordance with our findings, van Roest and colleagues310 
recently found that the primary site of origin for the periampullary carcinomas was not 
significantly associated with survival (p=0.095) when adjusting for perineural growth, 
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resection margin involvement, lymph node status, and angioinvasion. In our study (paper 
III), we reported that there were significant associations between histologic type of 
differentiation and the prognostic determinants reported by van Roest and colleagues, and 
this probably explains why tumour origin rendered insignificant when adjusting for the 
other factors in the study by Roest and colleagues. 
Paper IV evaluated the usefulness of molecular markers in classification and 
prognosis of pancreatic head adenocarcinomas. Although immunostaining is often used to 
confirm the finding of a specific histologic type, previous reports on differentiation markers 
in specimens from pancreatic head and periampullary resections have low sensitivity and/or 
specificity148,156,188,191,192,200,202,223,311-315, even when evaluating combined marker 
expression156,192,223,313-315.  We demonstrated that immunohistochemical analysis is not 
necessary to determine the histologic type of differentiation, although specific 
immunohistochemical phenotypes may identify patients with poor versus favourable 
prognosis among those who have pancreatobiliary-type tumours or intestinal-type tumours, 
respectively. 
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Conclusions 
Referring to the aims stated on page 29, the following conclusions can be drawn. 
 
1. Non-curative (R1) resection is most often due to tumour involvement of the 
retroperitoneal resection margin (in 32 of 40 R1 resections, 80%; paper I). Resection 
margin involvement, and retroperitoneal margin involvement in particular, 
independently predicts a poor prognosis after curative-intent (R0 and R1) 
pancreatoduodenectomy. Obtaining a curative (R0) resection was found to be 
significantly more important for patients who have ampullary tumours than for patients 
who have pancreatic tumours. 
 
2. Standardised histopathologic reporting was more important than institutional volume for 
completeness of histopathologic reporting and accuracy of survival estimates (paper II), 
particularly with respect to lymph node staging. 
 
3. Interobserver variation in classification of the cancer origin is not only dependent on 
differences between independent reviewers in judgement of histopathologic slides. It is 
also dependent on the methods and extent of evaluation of clinical, surgical, and 
macroscopic characteristics, as well as the appropriateness of histopathologic specimen 
dissection and the adequacy in preparation of microscopic slides (papers I and III). The 
histologic type of differentiation is easier to determine and may also be a better 
prognostic indicator than the assumed anatomic tumour origin (paper III). 
 
4. Immunohistochemical evaluation of molecular markers was not found necessary to 
determine the histologic type of differentiation (paper IV). However, immunostaining 
for the mucin proteins MUC1 and MUC4 may be used to identify patients with 
particularly poor prognosis after pancreatoduodenectomy for adenocarcinoma. 
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Abstract
Background: The retroperitoneal margin is frequently microscopically tumour positive in non-curative periampullary
adenocarcinoma resections. This margin should be evaluated by serial perpendicular sectioning. The aim of the study was to
determine whether retroperitoneal margin involvement independently predicts survival after pancreaticoduodenectomy within
a framework of standardized assessment of the resected specimens.
Methods: 114 consecutive macroscopically margin-free periampullary adenocarcinomas were examined according to a
prospective standardized protocol for histopathologic evaluation. The retroperitoneal margin was assessed by serial
perpendicular sectioning. The periampullary cancer origin (pancreas, ampulla, distal bile duct or duodenum) was registered
prospectively and reevaluated retrospectively. Associations between histopathologic factors were evaluated by Chi-square test,
Fisher's exact test, Kruskal-Wallis test, and Mann-Whitney test, as appropriate. Survival curves were calculated by the Kaplan-
Meier method and compared using the log-rank test. Associations between histopathologic factors and survival were also
evaluated by unadjusted and adjusted Cox regression analysis, including stepwise variable selection, in order to identify factors
that independently predict a poor prognosis after periampullary adenocarcinoma resections.
Results: Microscopic resection margin involvement (R1 resection) was present in 40 tumours, of which 32 involved the
retroperitoneal margin. Involvement of the retroperitoneal margin independently predicted a poor prognosis (p = 0.010; HR
1.89; CI 1.16–3.08) after presumed curative (R0 and R1) resection. In microscopically curative (R0) resections (n = 74),
pancreatic tumour origin was the only factor that independently predicted a poor prognosis (p < 0.001; HR 4.71 for pancreatic
versus ampullary; CI 2.13–10.4).
Conclusion: Serial perpendicular sectioning of the retroperitoneal resection margin demonstrates that tumour involvement of
this margin independently predicts survival after pancreaticoduodenectomy for adenocarcinoma. Periampullary tumour origin is
the only histopathologic factor that independently predicts survival in microscopically curative (R0) resections.
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Background
Resectable primary adenocarcinomas located in the pan-
creatic head may derive from the pancreatic tissue, the
hepatopancreatic ampulla, the distal bile duct or the duo-
denum, and collectively these cancers may be referred to
as periampullary adenocarcinomas [1]. The precise
tumour origin is often impossible to determine prior to
surgery, and pancreaticoduodenectomy is thus performed
for all four types irrespective of tumour origin. Complete
tumour removal is one of the most important factors
influencing long-term survival after resection [2-6]. How-
ever, even after margin-free resection (R0 resection) the
recurrence rate is high and the majority of patients suc-
cumb to the disease within 5 years [2-6].
The reported proportion of patients having tumour
involved resection margins (R1 resection) after pancreati-
coduodenectomy varies considerably, in the range
31–85% for pancreatic tumours and 2–27% for ampul-
lary tumours [1,2,7-10]. The large variation may partly be
explained by underreporting of R1 resections due to non-
standardized protocols for microscopic evaluation of the
resection margins [9,11]. Furthermore, little is known
about the relative importance of the different resection
margins in R1 resections as determinants for survival
[5,9,12]. The techniques employed for examination of the
resected specimens clearly influence the reported rates of
R0/R1 resections. Several groups have suggested guide-
lines for standardization of histopathologic assessment
[13-19]. However, the retroperitoneal resection margin,
which is most often involved in non-curative resections
[5,13,20,21], is often not systematically evaluated in stud-
ies reporting histopathologic prognostic factors after pan-
creaticoduodenectomy [22-25].
The considerable variations in reported percentages of R1
resections for pancreatic and ampullary tumours may also
be explained by difficulties in determining the cancer ori-
gin. Even after systematic histopathologic evaluation, the
precise origin may be impossible to determine due to
tumour destruction of normal periampullary anatomy
[13,26-29]. There is also considerable normal variation of
periampullary ductal structures, adding to the difficulties
[26]. The common practice of reporting data on only a
single periampullary subtype makes comparison of stud-
ies difficult due to the expected variations in inclusion and
exclusion criteria for periampullary subtypes. For exam-
ple, survival after resection of ductal pancreatic adenocar-
cinoma may be overestimated if ampullary cases are not
adequately excluded [30]. Adjusted Cox regression analy-
sis [31] including tumour origin as a covariate adjusts for
some of the uncertainties regarding periampullary sub-
type classification, and also eliminates redundant or
duplicate information resulting from associations
between tumour origin and other covariates. Thus, we
propose that survival analysis of all periampullary adeno-
carcinomas should include the tumour origin as a covari-
ate rather than only presenting the results from separate
subgroups.
Starting from 1998, we have employed a standardized
protocol for evaluation of pancreaticoduodenectomy
specimens, including serial perpendicular sectioning of
the retroperitoneal resection margin and prospective eval-
uation of the cancer origin. The aim of this study was to
investigate whether tumour involvement of the retroperi-
toneal margin is an independent prognostic factor for sur-
vival after resection of periampullary adenocarcinoma.
Tumour origin was included as a covariate both in the
overall adjusted analysis of all presumed curative (R1 and
R0) periampullary resections and in a separate subgroup
analysis of R0 resections.
Methods
Patient cohort
The study was approved by the National Committees for
Research Ethics in Norway, project number S-05081, and
was in compliance with the Helsinki Declaration. From
1998 to 2004, 161 consecutive patients underwent pan-
creaticoduodenectomy at the Department of Surgery, Rik-
shospitalet University Hospital, a third-level referral
hospital. Of these, 114 patients (55 women and 59 men;
median age 68 years; range 41–82) had primary adenocar-
cinoma with macroscopically free margins (R0 or R1
resections). Seventy six of the 114 included patients died
before the end of the study, and the remaining 38 patients
were followed up for a median of 4.8 years (range
1.6–8.4). None of the patients received preoperative
chemo- or radiotherapy. During the study period,
national guidelines did not recommend postoperative
chemo- or radiotherapy. All patients underwent a stand-
ard Whipple's procedure including a distal gastrectomy.
An effort was made to skeletonize the superior mesenteric
and portal veins and the superior mesenteric artery in all
cases, without performing extended lymphadenectomy.
There were three cases with vascular resection (of which
one tumour originated in the peripapillary duodenum
and two were pancreatic). Intra-operative frozen sections
from the bile duct and pancreatic neck resection margins
were performed upon macroscopic suspicion of tumour
involvement. Perioperative death (in-hospital death or
death within 30 days of operation) was 3.5% (4/114).
Cases with perioperative death were included in the sur-
vival analysis.
Standardized protocol for examination of resection 
specimens
In this study, we defined the retroperitoneal margin as the
area of sharp dissection in the peripancreatic fatty tissue
behind the pancreatic head and lateral to the mesenteric
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vessels (Figure 1). After fixation of the pancreaticoduo-
denectomy specimen in formalin, one block from the
pancreatic neck and distal bile duct resection margins,
respectively, was secured. These sections were taken paral-
lel to the resection margins (shave sections). One block
from the stomach and small bowel resection margins,
respectively, was also secured. The retroperitoneal margin
was identified and inked, and a section parallel to the
resection margin (5–10 mm thick slice) was made, from
which serial perpendicular sectioning into 5 mm thick
slices was performed (Figure 2) [11,13]. The pancreatic
duct and the distal bile duct, and their orifice(s) at the
duodenal surface were identified, and probes were
inserted in order to locate any obstruction within these
ducts. A section parallel to the ductal structures, including
duodenum, ampulla, distal bile duct and pancreatic
parenchyma on a single slide, was made in order to dem-
onstrate the tumour's relation to each of these potential
sites of origin (Figure 3) [1]. Cross sections into the
tumour were then made to evaluate tumour size and
potential infiltration into adjacent structures. Lymph
nodes were sampled from the duodenal knee and large
and lesser curvatures of the stomach.
Histopathologic evaluation of specimens
The following histopathologic factors were prospectively
registered by routine examination: Tumour origin, maxi-
mum tumour diameter, degree of differentiation,
perineural infiltration, vascular infiltration, dysplasia or
other tumour associated pathologic changes, lymph node
status, and resection margin status (pancreatic, bile duct,
stomach, jejunal and retroperitoneal margins evaluated
independently). All registrations were later reevaluated by
an experienced pathologist. Finally, tumour origin was
independently assessed by a second experienced patholo-
gist. The cancer origin was determined by assessing
tumour location relative to ductal anatomy and duodenal
and pancreatic parenchyma, and by noting any associated
epithelial dysplasia or in situ neoplasia. Upon disagree-
ment, consensus was reached by discussion. All tumours
were assigned to one of the four types using this approach.
The final allocation of tumour origin corresponded with
the initial prospective evaluation in 89 of 114 specimens
(78%).
An R0 resection was defined as both macro- and micro-
scopically free margins. An R1 resection was defined as
tumour within 1 mm of a resection margin upon micro-
scopic examination of haematoxylin and eosin stained
sections. An R2 resection was defined as macroscopic
residual tumour at the operative site, as described in the
surgeon's operative report. Degree of differentiation was
classified according to a two-score system as proposed by
Lüttges et al. [32], distinguishing high-grade from low-
grade carcinomas by presence or no presence, respectively,
of areas with poorly differentiated tumour.
Statistical analysis
Survival data were obtained from the National Registry of
Norway. The Kaplan-Meier method was used to calculate
curves for overall survival and to estimate median sur-
vival. Survival curves were compared using the log-rank 
Close-up of the posterior aspect of a pancreaticoduodenec-tomy specimen fr m a patient with adenocarcin ma in th  pancreati  head without tumour in iltrati n in o the retro-eritoneal argin, before (A) and after (B) fixati n in fo ma-linFigu e 1
Close-up of the posterior aspect of a pancreaticoduodenec-
tomy specimen from a patient with adenocarcinoma in the 
pancreatic head without tumour infiltration into the retro-
peritoneal margin, before (A) and after (B) fixation in forma-
lin. The retroperitoneal resection margin was defined as the 
area of sharp dissection (white stapled area) in the peripan-
creatic fatty tissue behind the pancreatic head and lateral to 
the mesenteric vessels. In this case this area was relatively 
small. In cases with tumour infiltration or inflammation 
involving the posterior aspect of the pancreatic head, the size 
of this sharply dissected area may extend into the superior 
mesenteric vein groove (A, indicated by the forceps) or to a 
larger part of the posterior pancreatic surface (B, red stapled 
area). The black stapled area (A, B) indicates the pancreatic 
neck transection margin.
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Whole-mount section parallel to the ampulla, distal bile duct and pancreatic duct, demonstrating periampullary tumour growth relative to ductal a a omy, for determina ion f the site f cancer originFigur 3
Whole-mount section parallel to the ampulla, distal bile duct 
and pancreatic duct, demonstrating periampullary tumour 
growth relative to ductal anatomy, for determination of the 
site of cancer origin. (A) White areas on the macroscopic 
photograph indicate possible tumour growth. (B) On micro-
scopic examination, this tumour was found to originate from 
the peri-papillary duodenum (du), although it also involved 
the entire ampullary region (stapled area), and the distal por-
tions of the distal bile duct (bd) and pancreatic duct (pd). In 
such cases, and in particular if epithelial dysplasia or in situ 
neoplasia also affects more than one periampullary subloca-
tion, determination of the cancer origin may be difficult, and 
virtually impossible without systematic histopathologic exam-
ination.
(A) Posterior view of a pancreaticoduodenectomy specimen with periampullary adenocarcinoma infiltrating the retrop ri-toneal resection margiFigur  2
(A) Posterior view of a pancreaticoduodenectomy specimen 
with periampullary adenocarcinoma infiltrating the retroperi-
toneal resection margin. The specimen includes the pyloric 
part of the stomach (st), the duodenum (du), adipose tissue 
which is part of the greater omentum, and the head and unc-
inate process of pancreas. The retroperitoneal resection 
margin was identified and marked with ink. (B) A section par-
allel to this resection margin was made. (C) Perpendicular 
sections of the retroperitoneal resection margin demon-
strate pancreatic parenchyma and connective tissue, includ-
ing fat, vessels and nerves, with infiltration of tumour cells < 
1 mm from the inked margin (visible on higher magnification), 
thus revealing a non-curative (R1) resection.
BMC Cancer 2008, 8:5 http://www.biomedcentral.com/1471-2407/8/5
Page 5 of 10
(page number not for citation purposes)
test. Associations between categorical variables were
examined using Chi-square test and Fisher's exact test.
Mann-Whitney test and Kruskal-Wallis test were per-
formed to compare tumour diameter (measured as a con-
tinuous variable) between groups of independent
samples. The factors evaluated were: tumour origin, max-
imum tumour diameter, degree of differentiation,
perineural infiltration, vascular infiltration, lymph node
status, and resection margin status (pancreatic, bile duct,
and retroperitoneal margins; no tumour infiltrated the
stomach or jejunal resection margins).
Cox regression models were fitted in order to estimate
unadjusted and adjusted survival after presumed curative
(R0 and R1) resection, together with the hazard ratios
with their 95% confidence intervals. For categorical varia-
bles, the group with the best prognosis in unadjusted
analysis was set as reference. Hazards were proportional
for all covariates, allowing inclusion of covariates in the
adjusted analysis without need for stratification. All the
examined histopathologic factors were significant in the
unadjusted analysis and were thus included in the
adjusted models. Two separate models were fitted for
adjusted analysis of all histopathologic factors, consider-
ing the resection margins collectively (R1 versus R0) and
individually (retroperitoneal margin free versus involved,
and pancreatic margin free versus involved; omitting the
stomach and duodenal resection margins, that had no
cases with tumour involvement, and the distal bile duct
margin, that had only two cases with tumour involve-
ment). Factors were evaluated using forward stepwise var-
iable selection, thus avoiding inclusion of variables with
redundant prognostic information. In order to estimate
the relative importance of the individual resection mar-
gins, the adjusted analysis was repeated after exclusion of
the seven patients that had multiple margin tumour
involvement. This analysis gave very similar results, with
the same covariates in the final adjusted models as in the
analysis including all 114 patients. These seven patients
were thus not excluded from the analysis. A separate
adjusted Cox regression subgroup analysis was performed
for R0 resected patients in order to determine the factors
that were independently associated with survival in cura-
tive resections. The proportional hazards assumption was
evaluated by examination of log minus log plots (see
Additional file 1: Verification of the proportional hazards
assumption). Likelihood ratio test was computed to
examine possible interactions between covariates (see
Additional file 2: Evaluation of possible interaction
between tumour origin and resection margin status).
All statistical analyses were performed with SPSS 15.0 for
Windows software (SPSS Inc., Chicago, Illinois, USA). A
two-sided p < 0.05 was considered statistically significant.
Results
In this study of 114 macroscopically margin-free pancrea-
ticoduodenectomies, 65% and 35% were R0 and R1 resec-
tions, respectively (Table 1). The retroperitoneal margin
was involved by tumour infiltration in 80% of the R1
resections (32 of 40). Seven of the thirty-two tumours that
infiltrated the retroperitoneal margin also infiltrated the
pancreatic neck transection margin (of which two also
infiltrated the distal bile duct margin). Resection margin
involvement was significantly associated with each of the
other prognostically poor histopathologic factors
(regional lymph node involvement, p < 0.001; vessel infil-
tration, p = 0.001; perineural infiltration, p < 0.001; pres-
ence of areas with poor differentiation, p = 0.005; large
tumour, p = 0.013). Resection margin involvement was
most frequent when the tumour originated from the distal
bile duct or pancreas (p = 0.009).
Unadjusted overall survival
In the unadjusted Cox regression analysis of 114 periam-
pullary adenocarcinomas, tumour involvement of the
resection margins predicted a poor prognosis compared to
margin-free resections (Figure 4; see also Additional file 3:
Unadjusted analysis of histopathologic prognostic fac-
tors), both when the resection margins were modelled
collectively (R1 versus R0 resections, p < 0.001) and sepa-
rately (retroperitoneal margin involved versus free, p <
0.001; pancreatic neck transection margin involved versus
free, p = 0.003; bile duct resection margin involved versus
free, p = 0.005). As expected, patients with cancer originat-
ing from the pancreas had the worst prognosis, with a
median postoperative survival of 1.2 years (95% CI:
1.0–1.4), compared to 4.9 years (95% CI: 2.4–7.4) for
ampullary tumours (p < 0.001). However, although the
prognosis for R0 resected patients was significantly associ-
ated with tumour origin (p < 0.001), the prognosis after
non-complete (R1) resections did not depend on tumour
origin (p = 0.45). Comparing resections of pancreatic and
ampullary tumours (Figure 5), resection status was found
to be a more powerful predictor for survival for patients
with ampullary tumour (p < 0.001, Figure 5B) than for
patients with pancreatic tumour (p = 0.30, Figure 5A).
Patients with ductal pancreatic adenocarcinoma had an
estimated, statistically non-significant survival benefit of
only five months for curative versus non-curative resec-
tion (p = 0.30, Figure 5A), while most of the patients with
R0 resected ampullary tumours were still alive by the end
of the study (19 of 31; median survival not reached, >5
years) and all patients with R1 resected ampullary
tumours were dead by the end of the study (10 of 10) (p
< 0.001, Figure 5B). The interaction between resection
margin status and tumour origin for these two groups was
statistically significant (p = 0.009).
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Adjusted analysis of presumed curative resections
In order to establish whether the retroperitoneal resection
margin was an independent prognostic factor for clini-
cally resectable periampullary adenocarcinomas (R0 and
R1 resections), we performed adjusted Cox regression
analysis including in a forward variable selection process
all the variables that were significant in the unadjusted
analysis. This resulted in the adjusted models (Table 2), in
which tumour involvement of one or more resection mar-
gins (Table 2A), and the retroperitoneal margin in partic-
ular (Table 2B), independently predicted a poor prognosis
after pancreaticoduodenectomy for periampullary adeno-
carcinoma (p = 0.010), adjusting for lymph node status
and perineural infiltration (p < 0.01 for each, in both
adjusted models).
Survival after microscopically margin-free resections
Finally, we performed a subgroup analysis of all patients
that underwent a curative (R0) resection (n = 74). Pancre-
atic tumour origin was significantly associated with each
of the other prognostically poor histopathologic factors
(regional lymph node involvement, p = 0.008; vessel infil-
tration, p = 0.004; perineural infiltration, p < 0.001; pres-
ence of areas with poor differentiation, p = 0.001; large
tumour, p < 0.001). Although these factors were signifi-
cantly associated with survival in unadjusted analysis,
adjusted analysis with stepwise forward variable selection
resulted in a final model that included only tumour ori-
gin, which was thus the only independent predictor of
survival after curative pancreaticoduodenectomy in the
present study. The hazard ratio for R0 resected ductal pan-
creatic versus ampullary adenocarcinoma was 4.71 (95%
CI: 2.13–10.4, p < 0.001). Median survival for patients
with R0 resected pancreatic cancer was 1.3 years (95% CI:
1.0–1.6) while patients with R0 resected non-pancreatic
cancer survived median more than 5 years (median sur-
vival not reached for ampullary and duodenal cases; p <
0.001).
Discussion
Standardized protocols for evaluation of the resection
margins should be mandatory in studies reporting prog-
nostic data on periampullary adenocarcinomas
[1,9,13,19,33]. The retroperitoneal margin should be
evaluated by serial perpendicular sectioning [13]. Insuffi-
cient examination of the retroperitoneal margin might
lead to underreporting of R1 resections[9,11]. Although
most investigators report overall resection margin
involvement to be an independent prognostic factor
[2,3,7,8,34], some investigators have concluded other
Table 1: Origin of tumour versus margin involvement and other histopathologic characteristics in 114 periampullary 
adenocarcinomas
Origin of tumour Total
(n = 114)
p-valuea
Ampulla
(n = 41)
Duodenum
(n = 16)
Distal bile duct
(n = 17)
Pancreas
(n = 40)
Margin involvement 0.009b
Any margin (R1 resections) 10 2 10 18 40
Retroperitoneal 9 1 8 14 32
Pancreatic neck 2 1 5 7 15
Distal bile duct 0 0 0 2 2
No margin (R0 resections) 31 14 7 22 74
Other histopathologic characteristics
Nodal status 0.005
N1 17 10 7 31 65
N0 24 6 10 9 49
Degree of differentiation 0.009
Poor 8 5 9 21 43
High or moderate 33 11 8 19 71
Vessel involvement 0.013
yes 9 4 9 21 43
no 32 12 8 19 71
Perineural infiltration <0.001
yes 13 6 11 32 62
no 28 10 6 8 52
Tumour size <0.001c
large (diameter  2.6 cm) 8 11 6 23 48
small (diameter  2.5 cm) 33 5 11 17 66
aChi-square test, when not otherwise specified
bR1 vs R0 resection
cMeasured as a continuous variable, Kruskal-Wallis test and Mann-Whitney test (pancreatic vs non-pancreatic)
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Overall survival for R0 versus R1 resection of tumours originating in (A) the pancreas (n = 41; p < 0.001)Figure 5
Overall survival for R0 versus R1 resection of tumours originating in (A) the pancreas (n = 40; p = 0.30) and (B) the ampulla (n 
= 41; p < 0.001).
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wise [6,22]. Specific data on the retroperitoneal margin
were not included in these reports. In the present study we
have used a standardized systematic protocol for his-
topathologic assessment of resection margin involve-
ment, with special attention to the retroperitoneal
margin. Our main finding was that resection margin
involvement, and retroperitoneal margin involvement in
particular, independently predicts a poor prognosis in
curative-intent (R0 and R1) resections for periampullary
adenocarcinoma. In addition, we found that the anatomic
tumour origin was the only independent prognostic factor
in macro- and microscopic margin-free (R0) resections.
A problem when considering standardization of his-
topathologic reporting of pancreaticoduodenectomy
specimens is that the definition of the retroperitoneal
resection margin varies considerably. Some investigators
define this margin simply as "the peripancreatic fat tissue
behind the head of the pancreas [13,15]." Others include
only the tissue directly adjacent to the proximal 3–4 cm of
the superior mesenteric artery [16,19], sometimes with a
clear distinction between the "retroperitoneal" and the
"posterior pancreatic" resection margins [16]. The retro-
peritoneal margin is also often synonymously referred to
as the "posterior," "mesenteric" or "uncinate" margin
[14,17]. Some have advocated examination of the whole
peripancreatic fatty tissue resection margin [20,21,35].
Verbeke et al. [9] recently evaluated a standardized proto-
col for examination of the circumferential resection mar-
gin, subdividing this margin into the anterior, posterior
and superior mesenteric vein groove circumferential resec-
tion margins. In cases with inflammation and tumour
invasion it may be difficult to distinguish between such
distinct resection margins. Most important for evaluation
of tumour margin infiltration is the area of sharp dissec-
tion, the extent of which varies depending on the degree
of inflammation and tumour invasion. In our study, we
thus widened the strictest definition of the retroperitoneal
resection margin, but omitted separate analysis of each
aspect of the circumferential peripancreatic margin in
order to avoid extensive sampling.
The use of non-standardized protocols for histopatho-
logic assessment may not only cause inconsistencies in
the reporting of R0 versus R1 rates, but could also lead to
differences with respect to classification of the anatomic
site of tumour origin [1,13]. In the present study, tumour
origin did not independently predict survival in presumed
curative (R0 and R1) resections, although this factor was
borderline significant when evaluated in a base model
adjusting for all other histopathologic factors. There are
probably two reasons for this. First, patients with pancre-
atic tumours (with the poorest prognosis in unadjusted
analysis) frequently had resection margin involvement
(45%). Thus, adjusting for resection margin status in the
adjusted analysis renders tumour origin statistically non-
significant. Second, in the unadjusted analysis, tumour
origin was significantly associated with survival only in
R0, not R1, resections. Consequently, in the adjusted anal-
ysis for R0 resected patients, tumour origin was the only
histopathologic factor that independently predicted long-
term survival after pancreaticoduodenectomy.
Interestingly, patients with ampullary adenocarcinoma
had a considerable survival benefit of a retroperitoneal
margin-free resection, while a free margin at this site was
only non-significantly associated with survival for
patients who had adenocarcinoma originating in the pan-
creas. Even when considering the resection margins col-
lectively, we found only a non-significant tendency
towards some five months benefit of having a margin-free
resection in the pancreatic group. This is in line with pre-
vious reports, since the difference between median sur-
vival of patients with margin-free versus margin-involved
resections from ductal pancreatic adenocarcinoma has
typically been reported to be about half a year [5,8,9,36-
38]. In a large, multicenter, prospective study of resected
pancreatic cancer, Neoptolemos et al. [36] found that
resection margin status was not an independent predictor
of survival in ductal pancreatic adenocarcinoma. The ret-
roperitoneal resection margin was however not systemat-
ically evaluated, and the R0 rate was exceptionally high
(81%), possibly underestimating the rate of R1 resections
[9]. In a study primarily comparing pancreaticoduodenec-
tomy with or without vascular resection, Tseng et al. [37]
reported that retroperitoneal margin involvement was not
an independent prognostic factor in patients with pancre-
atic adenocarcinoma. However, stepwise variable selec-
tion was not performed, and the definition of the
retroperitoneal margin was restricted to the area directly
adjacent to the superior mesenteric artery. Evaluating
individual resection margins in 160 resected pancreatic
adenocarcinomas, Kuhlmann et al. [5] found that R0
resection independently predicted a favourable prognosis,
Table 2: Adjusted Cox regression analysis of histopathologic 
prognostic factors (n = 114)
HR 95% CI p-value
A. Model 1
Resection margin status R1 (vs R0) 1.90 1.17–3.10 0.010
Lymph nodes N1 (vs N0) 2.24 1.28–3.91 0.005
Perineural infiltration yes (vs no) 2.22 1.31–3.75 0.003
B. Model 2
Retroperitoneal margin involved 
(vs free)
1.89 1.16–3.08 0.010
Lymph nodes N1 (vs N0) 2.29 1.32–3.99 0.003
Perineural infiltration yes (vs no) 2.32 1.38–3.92 0.002
HR, hazard ratio. HR > 1 indicates increased probability of death 
compared to the reference group
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but did not report the independent prognostic impor-
tance for survival of the retroperitoneal margin in particu-
lar. Thus, to establish whether or not involvement of the
retroperitoneal resection margin independently predicts
the prognosis also in ductal pancreatic adenocarcinoma,
larger studies using standardized evaluation of both
tumour origin and the individual resection margins
should be performed.
Conclusion
Systematic histopathologic evaluation confirms that
resection margin involvement, and retroperitoneal mar-
gin involvement in particular, independently predicts a
poor prognosis in curative-intent (R0 and R1) resections
of periampullary adenocarcinoma. Involvement of the
retroperitoneal margin is frequent in pancreatic, distal
bile duct and ampullary tumours, and serial perpendicu-
lar sectioning of the retroperitoneal margin should thus
be performed in all pancreatic head adenocarcinomas to
avoid underestimation of R1 resections.
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Verification of the proportional hazards assumption (n=114)
Covariates HR
Origin
- duodenal vs. ampullary 0.57 0.21 - 1.52
- distal bile duct vs. ampullary 0.51 0.23 - 1.17
- pancreatic vs. ampullary 1.19 0.62 - 2.31
Resection margin status 1.82 1.09 - 3.06
Lymph node status 1.55 0.84 - 2.86
Poor differentiation 1.82 1.06 - 3.12
Vessel involvement 1.72 1.02 - 2.92
Perineural infiltration 1.66 0.92 - 3.02
Tumour diameter (in cm) 1.23 0.96 - 1.58
Resection margin status 1.74 1.03 - 2.93
Lymph node status 1.72 0.90 - 3.27
Poor differentiation 1.83 1.06 - 3.15
Vessel involvement 1.65 0.96 - 2.84
Perineural infiltration 1.59 0.86 - 2.93
Tumour diameter (in cm) 1.21 0.94 - 1.57
Origin
- duodenal vs. ampullary 0.57 0.21 - 1.52
- distal bile duct vs. ampullary 0.52 0.22 - 1.18
- pancreatic vs. ampullary 1.14 0.58 - 2.24
Lymph node status 1.58 0.85 - 2.94
Poor differentiation 1.91 1.11 - 3.28
Vessel involvement 1.66 0.97 - 2.84
Perineural infiltration 1.62 0.90 - 2.95
Tumour diameter (in cm) 1.22 0.95 - 1.56
Origin
- duodenal vs. ampullary 0.51 0.18 - 1.42
- distal bile duct vs. ampullary 0.50 0.22 - 1.14
- pancreatic vs. ampullary 1.21 0.62 - 2.35
Resection margin status 1.85 1.10 - 3.12
Poor differentiation 1.90 1.11 - 3.27
Vessel involvement 1.77 1.04 - 3.00
Perineural infiltration 1.66 0.91 - 3.01
Tumour diameter (in cm) 1.19 0.91 - 1.54
Origin
- duodenal vs. ampullary 0.56 0.21 - 1.47
- distal bile duct vs. ampullary 0.56 0.24 - 1.28
- pancreatic vs. ampullary 1.17 0.60 - 2.28
Resection margin status 1.74 1.03 - 2.94
Lymph node status 1.53 0.83 - 2.82
Poor differentiation 1.75 1.02 - 3.02
Perineural infiltration 1.71 0.94 - 3.13
Tumour diameter (in cm) 1.23 0.96 - 1.58
Origin
- duodenal vs. ampullary 0.57 0.21 - 1.54
- distal bile duct vs. ampullary 0.50 0.22 - 1.14
- pancreatic vs. ampullary 1.18 0.61 - 2.30
Resection margin status 1.84 1.10 - 3.09
Lymph node status 1.50 0.82 - 2.75
Poor differentiation 1.95 1.13 - 3.37
Vessel involvement 1.75 1.03 - 2.98
Tumour diameter (in cm) 1.24 0.96 - 1.60
Origin
- duodenal vs. ampullary 0.62 0.23 - 1.70
- distal bile duct vs. ampullary 0.54 0.24 - 1.24
- pancreatic vs. ampullary 1.16 0.59 - 2.29
Resection margin status 1.86 1.10 - 3.13
Lymph node status 1.50 0.81 - 2.77
Vessel involvement 1.67 0.98 - 2.86
Perineural infiltration 1.73 0.95 - 3.16
Tumour diameter (in cm) 1.21 0.94 - 1.55
Base model 1, stratified by resection status
Base model 1, stratified by presence of poor differentiation
Base model 1, stratified by perineural infiltration
Base model 1, stratified by vessel infiltration
Base model 1, stratified by lymph node status
Graphical evaluation
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Evaluation of possible interaction between tumour origin and resection margin status
A. Analysis including all four tumour origins (ampulla, duodenum, distal bile duct, 
pancreas) and resection margin status (free vs involved) (n=114)
df p-value HR
95.0% CI for HR
Lower Upper
Covariates (assuming no interaction)
R-status 1 0.000 2.61 1.59 4.27
Origin 3 0.002
Origin(duodenum vs ampulla) 1 0.699 1.17 0.54 2.54
Origin(distal bile duct vs ampulla) 1 0.652 0.84 0.40 1.78
Origin(pancreas vs ampulla) 1 0.002 2.50 1.41 4.44
-2 Log Likelihood of model coefficients
607.31 4
Covariates (assuming interaction)
R-status 1 0.000 6.03 2.51 14.48
Origin 3 0.000
Origin(duodenum vs ampulla) 1 0.387 1.51 0.59 3.84
Origin(distal bile duct vs ampulla) 1 0.972 0.98 0.28 3.47
Origin(pancreas vs ampulla) 1 0.000 4.72 2.19 10.20
Origin*R-status 3 0.103
Origin(duodenum vs ampulla)*R-status 1 0.493 0.54 0.09 3.19
Origin(distal bile duct vs ampulla)*R-status 1 0.437 0.53 0.11 2.61
Origin(pancreas vs ampulla)*R-status 1 0.014 0.25 0.08 0.75
-2 Log Likelihood of model coefficients
601.24 7
Change in Chi-square
607.31 - 601.24 = 6.07 3 0.10<p<0.20*
B. Analysis including the two largest groups of tumour origin (ampulla, pancreas) and 
resection margin status (free vs involved) (n=81)
df p-value HR
95.0% CI for HR
Lower Upper
R-status 1 0.000 7.21 2.74 18.97
Origin 1 0.000 5.81 2.43 13.89
Origin*R-status 1 0.009† 0.20 0.06 0.67
* non-significant
† significant
Unadjusted analysis of histopathologic prognostic factors 
No of patients Median survival (years) HR
95% CI 
for HR p-value
A. R0 and R1 resections (n=114) 
R-status R0 (ref) 74 4.4
R1 40 1.2 2.82 1.78–4.49 < 0.001
Retroperitoneal margin free (ref) 82 2.8
involved 32 1.2 2.61 1.63–4.18 < 0.001
Pancreatic neck margin free (ref) 99 2.2
involved 15 1.2 2.45 1.35–4.43 0.003
Distal bile duct margin free (ref) 112 1.9
involved 2 0.6 8.27 1.88–36.4 0.005
Origin ampulla (ref) 41 4.9 < 0.001
duodenum 16 2.3 1.09 0.50–2.38 0.822
distal bile duct 17 2.5 1.20 0.58–2.49 0.615
pancreas 40 1.2 3.15 1.79–5.53 < 0.001
Lymph nodes N0 (ref) 49 NR
N1 65 1.3 3.30 1.97–5.53 < 0.001
Poor differentiation no (ref) 71 3.7
yes 43 1.2 2.59 1.64–4.11 < 0.001
Vessel involvement no (ref) 71 3.7
yes 43 1.3 2.80 1.76–4.47 < 0.001
Perineural infiltration no (ref) 52 5.4
yes 62 1.3 3.17 1.93–5.19 < 0.001
Tumour size (continuous) diameter (cm) 114 1.8 1.27 1.08–1.48 0.003
B. R0 resections (n=74) 
Origin ampulla (ref) 31 NR < 0.001
duodenum 14 5.0 1.51 0.59–3.84 0.389
distal bile duct 7 NR 1.00 0.28–3.55 0.998
pancreas  22 1.3 4.71 2.13–10.4 < 0.001
Lymph nodes N0 (ref) 41 NR
N1 33 1.7 2.89 1.51–5.55 0.001
Poor differentiation no (ref) 53 5.4
yes 21 1.3 2.94 1.54–5.62 0.001
Vessel involvement no (ref) 54 5.4
yes 20 1.3 2.43 1.24–4.75 0.009
Perineural infiltration no (ref) 43 6.0
yes 31 1.7 2.38 1.27–4.48 0.007
Tumour size (continuous) diameter (cm) 74 4.3 1.23 1.00–1.50 0.045
HR, hazard ratio. HR > 1 indicates increased probability of death compared to the reference group 
ref, reference for categorical variables 
NR, not reached 
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Abstract
Background: Resectable adenocarcinomas in the pancreatic head, by definition "periampullary",
originate from ampullary, duodenal, biliary, or ductal pancreatic epithelium. Typically, periampullary
adenocarcinomas have either intestinal or pancreatobiliary type of differentiation, and the type of
differentiation might be prognostically more important than the anatomic site of origin. The aim of
the study was to determine whether the histologic type of differentiation is an independent
prognostic factor in periampullary adenocarcinoma, and whether tumour origin predicts the
prognosis in pancreatobiliary type carcinomas independently of resection margin involvement,
tumour size, nodal involvement, perineural and vascular infiltration, and degree of differentiation.
Methods: Histopathologic variables in 114 consecutively resected periampullary adenocarcinomas
of pancreatobiliary (n = 67) and intestinal (n = 47) type differentiation were evaluated using a
standardized, systematic protocol for evaluation of the resected specimen (study group). Histologic
type of differentiation and tumour origin were compared as predictors of survival, and the results
were validated by comparison with a historical control group consisting of 99 consecutive
pancreaticoduodenectomies performed before standardization of histopathologic evaluation.
Associations between histopathologic variables were evaluated by Chi-square and Mann-Whitney
tests. Survival was estimated by the Kaplan-Meier method, comparing curves using log-rank test,
and by univariate and multivariable Cox regression analysis.
Results: Both in the study group (n = 114) and in the historical control group (n = 99), the
histologic type of differentiation independently predicted survival, while tumour origin predicted
survival only in univariate analysis. Independent adverse predictors of survival in the study group
were pancreatobiliary type differentiation (p < 0.001; HR 3.1; CI 1.8–5.1), regional lymph node
involvement (p < 0.001; HR 2.5; CI 1.5–4.4), vessel involvement (p = 0.012; HR 1.9; CI 1.2–3.1),
Published: 11 June 2008
BMC Cancer 2008, 8:170 doi:10.1186/1471-2407-8-170
Received: 7 July 2007
Accepted: 11 June 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/170
© 2008 Westgaard et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BMC Cancer 2008, 8:170 http://www.biomedcentral.com/1471-2407/8/170
Page 2 of 11
(page number not for citation purposes)
and increasing tumour diameter (measured in cm, p = 0.011; HR 1.3; CI 1.1–1.5). For
pancreatobiliary differentiated adenocarcinomas (n = 67), lymph node status, vessel involvement,
and tumour diameter remained independent prognostic factors, while tumour origin did not
independently predict the prognosis due to significant association with tumour size (p < 0.001) and
lymph node involvement (p = 0.004).
Conclusion: Pancreatobiliary versus intestinal type of differentiation independently predicts poor
prognosis after pancreaticoduodenectomy for periampullary adenocarcinoma. Lymph node
involvement, vessel infiltration, and increasing tumour diameter are adverse predictors of survival
in tumours with pancreatobiliary differentiation.
Background
Resectable primary adenocarcinomas located in the pan-
creatic head may derive from the pancreas, the ampulla,
the distal bile duct, or the duodenum. Collectively, these
tumours may be referred to as "periampullary" adenocar-
cinomas, of which those originating from the pancreas
have the worst prognosis [1]. The histopathologic and
biologic features associated with ductal pancreatic adeno-
carcinoma are different from non-pancreatic periampul-
lary tumours [2], and it has thus been customary to
consider these four subtypes of periampullary adenocarci-
noma as separate entities.
The precise origin of a periampullary adenocarcinoma is
often difficult to determine even with standardized his-
topathologic evaluation, particularly if the tumour is large
and involves more than one potential site of origin [3-8].
Tumour destruction of normal periampullary anatomy
[9], and presence of epithelial dysplasia in more than a
single periampullary compartment, occurs frequently.
Data in reports from a single subtype of periampullary
adenocarcinoma may be confounded by inadvertent
inclusion of tumours from other subtypes [6]. For exam-
ple, inadequate exclusion of ampullary carcinomas from
series of ductal pancreatic adenocarcinoma may lead to
overestimation of long-term survival [10].
In addition to the commonly evaluated histopathologic
factors, the histologic type of differentiation has been
shown to have biologic and prognostic relevance for amp-
ullary adenocarcinoma [6,7,11-14]. Kimura et al [13]
were the first to demonstrate that adenocarcinomas origi-
nating in the ampulla of Vater may be classified as having
either "intestinal" or "pancreatobiliary" type of differenti-
ation, of which patients with the latter type consistently
have been shown to have a worse prognosis [6,7,11-14].
This classification scheme is now widely accepted for
ampullary adenocarcinoma and has also been suggested
for extrahepatic bile duct carcinoma [15] and ductal pan-
creatic adenocarcinoma [16], but has not, to our knowl-
edge, been applied previously as a basis for analysis of
prognostic factors after periampullary adenocarcinoma
resections. In the present study, we hypothesized that an
evaluation of the histologic type of differentiation could
independently predict the prognosis after periampullary
resections and possibly give more precise information
about patient prognosis than evaluation of tumour origin.
Methods
Patients
Permission for the study was obtained by the National
Committees for Research Ethics in Norway. The patients
included in the study comprised all patients (n = 213)
with primary periampullary adenocarcinoma who under-
went a pancreaticoduodenectomy with curative intent
between 1980 and 2004 at Rikshospitalet University Hos-
pital, a third-level referral hospital. In January 1998, the
procedure for histopathologic reporting changed from a
non-standardized procedure to a standardized procedure,
in particular with respect to assessment of resection mar-
gins and tumour origin. Patients resected before and after
the first of January 1998 were therefore assigned to a his-
torical control group and a study group, respectively.
From 1998 to 2004 (study group), a total of 161 patients
underwent pancreaticoduodenectomy, of which 114
patients had primary adenocarcinoma with macroscopi-
cally free margins (R0 or R1 resections). Excluded cases
comprised patients with benign lesions (n = 22), neuroen-
docrine tumours (n = 9), invasive IPMN (n = 4), second-
ary carcinoma (n = 6), acinar cell carcinoma (n = 1),
adenosquamous carcinoma (n = 1), and non-curative
resection (i.e. macroscopic residual tumour, R2 resection;
n = 4). Histopathologic features were analyzed in order to
determine (1) whether the histologic type of differentia-
tion is an independent prognostic factor in periampullary
adenocarcinoma, and (2) to evaluate predictors of poor
prognosis in the subgroup of patients that had a pancrea-
tobiliary differentiated periampullary tumour.
Among the 114 patients in the study group, 82 were dead
by the end of the study and the remaining 32 were fol-
lowed for a median of 5.8 years (range 2.4–9.3). In the
subgroup of patients with pancreatobiliary type adenocar-
cinoma, 58 (of 67) were dead by the end of the study, and
the remaining 9 patients were followed median 6.1 years
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(range 3.5–8.7). The relatively many deaths and long fol-
low-up time for the censored cases thus permitted a sub-
group analysis of pancreatobiliary cases. Perioperative
death (in-hospital death or death within 30 days of oper-
ation) was 3.5% (4/114) in the study group, among
which three patients had ampullary tumour (3/41) and
one had tumour originating in ductal pancreatic tissue.
The patients resected between 1980 and 1997 (historical
control group, n = 99) provided a separate dataset in
which to validate the main conclusions from the study
group analysis. Tumour origin and differentiation type
was compared in the two datasets obtained by standard-
ized (study group) and non-standardized (historical con-
trol group) histopathologic evaluation, respectively. In
the historical control group, 89 (of 99) patients were dead
by the end of the study. The remaining 10 patients were
followed median 12.4 years (range 9.4–20.8). In the sub-
group of patients with pancreatobiliary type adenocarci-
noma, 69 (of 73) were dead by the end of the study, and
the remaining 4 patients were followed median 13.5 years
(range 10.4–20.8). Perioperative death was 4.0% (4/99)
in the historical control group. Cases with perioperative
death were included in the survival analyses. No patients
were lost to follow-up. Data from this series has been
reported previously [12].
Histopathologic assessment of specimens
In the study group, histopathologic factors were prospec-
tively registered by routine examination according to a
standardized, systematic protocol, and reevaluated retro-
spectively. The evaluated histopathologic factors were
tumour origin, histopathologic type of differentiation, pT
stage, maximum tumour diameter, resection margin
involvement (with special attention to the retroperitoneal
margin), perineural and vascular infiltration, regional
lymph node involvement, and degree of differentiation.
Approximately 15 tissue samples were taken from each
specimen including whole-mount blocks for most cases. A
section parallel to the ampulla, distal bile duct, pancreatic
duct, and parallel to the longitudinal duodenal axis was
made in order to demonstrate the tumour's relation to
each of these sites of potential tumour origin. The cancer
origin was determined by tumour location relative to duc-
tal anatomy and duodenal and pancreatic parenchyma,
and by associated epithelial dysplasia or in situ neoplasia.
Macroscopic pictures were also taken in selected cases.
The histologic type of differentiation was classified
according to the criteria first suggested by Kimura et al
[13], later revised by Albores-Saavedra et al [7] (figure 1).
In brief, pancreatobiliary tumours typically have simple or
branching glands and small solid nests of cells sur-
rounded by a desmoplastic stroma, have cuboideal to low
columnar epithelium arranged in a single layer without
nuclear pseudostratification, and the nuclei are rounded
but with marked variation in size and shape from one cell
to the next. Intestinal tumours typically resemble colon
cancer, may consist of solid nests with cribriform areas,
The two dominant types of histologic differentiation in periampullary adenocarcinomas: (A) The pancreatobiliary type typically has simple r branching gland  and small solid nests of cells surrounded by a desm pl tic stroma, and cuboideal to low colum-n r epith lium arranged in a single layer without nuclear pse dostratificati n, the nuclei round d but with marked variati n insiz and shape from one cell to the nextFigure 1
The two dominant types of histologic differentiation in periampullary adenocarcinomas: (A) The pancreatobiliary 
type typically has simple or branching glands and small solid nests of cells surrounded by a desmoplastic stroma, and cuboideal 
to low columnar epithelium arranged in a single layer without nuclear pseudostratification, the nuclei rounded but with marked 
variation in size and shape from one cell to the next. (B) The intestinal type typically resembles colon cancer, may consist of 
solid nests with cribriform areas, has tall and often pseudostratified columnar epithelium with oval nuclei located in the more 
basal aspects of the cytoplasm, and there may also often be presence of mucin.
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have tall and often pseudostratified columnar epithelium
with oval nuclei located in the more basal aspects of the
cytoplasm, and there may also often be presence of
mucin. Cases with mixed type differentiation were classi-
fied according to the dominant pattern, without perform-
ing cut-off optimalization prior to classification [17]. All
tumours were assigned to one of these two histologic
types of differentiation using this approach. In the histor-
ical control group (n = 99), cases with mixed type differ-
entiation were identified (n = 13; 7 predominantly
pancreatobiliary and 6 predominantly intestinal), and
survival was compared between cases with mixed and sin-
gle type of histologic differentiation in each group with
respect to the predominant histologic pattern of differen-
tiation. Patients with mixed type of differentiation had the
same prognosis as patients with only the predominant
type, eg. with only pancreatobiliary (p = 0.35) or only
intestinal (p = 0.21) type of differentiation, respectively,
thus indicating that classification based on the predomi-
nant pattern is applicable.
For both tumour origin and histologic type of differentia-
tion, the prospective registrations were reevaluated inde-
pendently by two experienced pathologists, a routine
pathologist (ST) and a senior pathologist (OPFC). The
routine pathologist reviewed only the microscopic slides
and was blinded towards clinical and macroscopic data,
while the senior pathologist also considered this informa-
tion when determining the anatomic site of tumour ori-
gin. Upon disagreement, final determination of tumour
origin and histologic type of differentiation was reached
by a second reevaluation of the slides and by reevaluation
of the histopathologic and operative reports.
In the historical control group (non-standardized proto-
col), all histopathologic reports and microscopic slides
were reevaluated by a single pathologist (OPFC). The his-
topathologic factors registered in this group were tumour
origin, histopathologic type of differentiation, maximum
tumour diameter, resection margin involvement,
perineural infiltration, regional lymph node involvement,
and degree of differentiation. Only pancreatobiliary or
intestinal adenocarcinomas were included in the analysis
of histopathologic factors. R2 cases were not excluded
from the analysis in the historical control group due to
non-standardized reporting for this cohort.
Statistical analysis
Survival data was obtained from the National Registry of
Norway, updated May 30, 2007. The Kaplan-Meier
method was used to calculate curves for overall survival
and to estimate median survival. Survival curves were
compared using the log-rank test. Associations between
categorical variables were examined using Chi-square test.
Mann-Whitney test was performed to compare maximum
tumour diameter (measured as a continuous variable)
between groups of independent samples. Interobserver
agreement was estimated by Cohen's kappa and catego-
rized as poor (kappa < 0.20), fair (0.21 < kappa < 0.40),
moderate (0.41 < kappa < 0.60), substantial (0.61 < kappa
< 0.80), or almost perfect (kappa > 0.80). Cox regression
models were fitted in order to estimate univariate and
multivariable survival, together with the hazard ratios and
their 95% confidence intervals. For categorical variables,
the group with the best prognosis in univariate analysis
was set as reference. The multivariable survival model
included all histopathologic factors, and the factors were
further evaluated using stepwise variable selection. The
model obtained from multivariable analysis in periamp-
ullary adenocarcinomas was tested in the ampullary sub-
group in order to evaluate how well multivariable analysis
with the same set of covariates could predict the prognosis
in this group for which classification by histologic type of
differentiation is already established. A separate multivar-
iable Cox regression subgroup analysis was performed for
patients with pancreatobiliary differentiated periampul-
lary adenocarcinoma in order to determine the factors
that were independently associated with survival in this
subgroup. Finally, the main findings obtained from the
study group analysis were validated by analysis of his-
topathologic factors in a historical control group.
Statistical analyses were performed in SPSS 15.0 for Win-
dows software (SPSS Inc., Chicago, Illinois, USA). R ver-
sion 2.3.1 (open source statistical software [18]) was used
for testing goodness-of-fit based on martingale residual
processes. For all tests, a two-sided p < 0.05 was consid-
ered statistically significant.
Results
In the study group comprising 114 periampullary adeno-
carcinomas, there were 67 with pancreatobiliary and 47
with intestinal histologic type of differentiation. These
consisted of 40 pancreatic, 41 ampullary, 17 common bile
duct, and 16 duodenal adenocarcinomas. Interobserver
agreement between the senior and routine pathologist
was almost perfect (kappa 0.90; 95% CI 0.82–0.99) for
determination of histologic type of differentiation, while
it was only fair (kappa 0.37; 95% CI 0.25–0.49) in classi-
fication of tumour origin. However, while the routine
pathologist who reevaluated the microscopic slides was
blinded towards clinical and macroscopic data, the senior
pathologist not only reevaluated the microscopic slides
but also considered information from the operative and
macroscopic reports. This type of information may be
more important for accurate tumour origin classification
than for histologic type classification. Thus, comparing
final consensus with the original reports, interobserver
agreement was substantial for both tumour origin classifi-
cation (25 reclassified cases; kappa 0.68; 95% CI 0.57–
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0.79) and histologic type classification (13 reclassified
cases; kappa 0.74; 95% CI 0.61–0.87).
Histopathologic prognostic factors in periampullary 
adenocarcinoma
As expected patients with pancreatic tumours had the
poorest prognosis among all periampullary adenocarci-
nomas in univariate analysis (p < 0.001, figure 2). Pancre-
atobiliary type of differentiation was an adverse predictor
of survival both in the whole cohort of periampullary ade-
nocarcinomas (p < 0.001, figure 3A) and in the ampullary
subgroup (p < 0.022, figure 3B).
Table 1 describes associations between histologic type of
differentiation and the other histopathologic factors.
Compared to intestinal type adenocarcinomas, pancreato-
biliary type adenocarcinomas significantly more often
showed presence of histopathologic features associated
with a poor prognosis, in particular resection margin
involvement, perineural infiltration, areas with poor dif-
ferentiation, advanced pT stage, and pancreatic tumour
origin (p < 0.001 for each).
In multivariable analysis adjusting for tumour origin, pT
stage, maximum tumour diameter, degree of differentia-
tion, regional lymph node metastasis, resection margin
involvement, vessel involvement, and perineural infiltra-
tion, the histologic type of differentiation was found to be
an independent predictor of survival (p = 0.032; HR 2.8;
95% CI 1.1–7.1), while tumour origin was only border-
line significant (p = 0.054). Stepwise backward variable
selection resulted in a final model that included the histo-
logic type of differentiation, which in fact was the strong-
est predictor of survival (table 2). The validity of the final
model was tested in the ampullary subgroup, confirming
that pancreatobiliary versus intestinal type of differentia-
tion was an independent adverse predictor of survival also
among these patients (p < 0.002; HR 4.0; 95% CI 1.6–
9.6).
Prognostic factors in pancreatobiliary differentiated 
periampullary adenocarcinomas
A separate analysis of histopathologic factors among the
patients who had pancreatobiliary adenocarcinoma (n =
67) was performed in order to identify prognostic factors
in this subgroup, and in particular, to evaluate whether
tumour origin could independently predict the prognosis
in pancreatobiliary type adenocarcinoma. In univariate
survival analysis, pancreatic tumour origin was signifi-
cantly associated with a poorer prognosis compared to
non-pancreatic tumour origin (table 3, figure 4A). Even
when adjusting for pT stage, the difference in survival
between patients who had pancreatic and non-pancreatic
tumour origin was statistically significant (p = 0.003; HR
= 2.9; 95% CI 1.4–6.0). However, adjusting for tumour
diameter instead of pT stage demonstrated that there was
in fact no survival difference between patients who had
pancreatic and non-pancreatic tumours (p = 0.25). The pT
staging for periampullary adenocarcinomas is based on
the assumption that clinical outcome depends more on
tumour extension beyond organ of origin than of tumour
size. An ampullary pT3 tumour slightly invading the pan-
creas may thus be as small as 1 cm, while pancreatic pT3
tumours are normally much larger. In the present sub-
group analysis of pancreatobiliary differentiated tumours,
pancreatic pT3 tumours were significantly larger than
non-pancreatic pT3 tumours (median diameter 3.5 versus
2.6 cm; p = 0.033).
Among all 67 pancreatobiliary differentiated adenocarci-
nomas, pancreatic tumours significantly more often than
non-pancreatic tumours had regional lymph node metas-
tasis (29/38 for pancreatic versus 12/29 for non-pancre-
atic tumours, p = 0.004) and were larger (median
diameter 3.1 cm for pancreatic versus 2.0 cm for non-pan-
creatic tumours, p < 0.001) (figure 4B). The differences in
survival seen among all cases (figure 4A) are thus related
to the differences in tumour diameter (figure 4B) between
Overall survival after pancreaticoduodenectomy for periamp-ullary adenocarcinoma (  = 114) originating in du denum (n = 16), mpull  (n = 41), distal bile duct (  = 17), and pancreas (n = 40) (  < 0.001)Figure 2
Overall survival after pancreaticoduodenectomy for 
periampullary adenocarcinoma (n = 114) originating 
in duodenum (n = 16), ampulla (n = 41), distal bile 
duct (n = 17), and pancreas (n = 40) (p < 0.001).
Patients at risk
ampulla 41 32 26 23 18 14
duodenum 16 14 9 7 6 5
distal bile duct 17 15 11 6 6 6
pancreas 40 24 9 6 2 0
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Overall survival after pancreaticoduodenectomy: (A) Periampullary adenocarcinoma (n = 114) with intestinal (n = 47) and pan-creatobilia y (n = 67) type of histologic differentiation (p < 0.001)Figure 3
Overall survival after pancreaticoduodenectomy: (A) Periampullary adenocarcinoma (n = 114) with intestinal (n = 47) 
and pancreatobiliary (n = 67) type of histologic differentiation (p < 0.001). (B) Ampullary adenocarcinoma (n = 41) with intesti-
nal (n = 28) and pancreatobiliary (n = 13) type of histologic differentiation (p = 0.02).
Patients at risk
intestinal 47 41 31 28 21 17
pancreatobiliary 67 44 24 14 11 8
Patients at risk
intestinal 28 24 20 19 14 11
pancreatobiliary 13 8 6 4 4 3
A BPeriampullary carcinoma Ampullary carcinoma
Table 1: Associations between histologic type of differentiation and other histopathologic factors in 114 periampullary 
adenocarcinomas
Differentiation of adenocarcinoma
intestinal pancreatobiliary p-valuea
Tumour origin ampulla 28 13 < 0.001
duodenum 16 0
distal bile duct 1 16
pancreas 2 38
pT stage pT1 10 2 < 0.001
pT2 20 9
pT3 8 46
pT4 9 10
Lymph node status N0 23 26 0.282
N1 24 41
Resection margin status R0 40 34 < 0.001
R1 7 33
Vessel involvement free 35 36 0.025
involved 12 31
Perineural infiltration no 35 17 < 0.001
yes 12 50
Areas with poorly differentiated tumour no 39 32 < 0.001
yes 8 35
Tumour size (maximum tumour diameter) small ( 2.5 cm) 31 35 0.108b
large (> 2.5 cm) 16 32
aChi-square test, when not otherwise specified
bMann-Whitney test (histologic type of differentiation vs tumour size measured as a continuous variable)
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non-pancreatic and pancreatic tumours. Selecting
tumours of comparable size (range 2.0–3.0 cm, n = 30)
demonstrated no difference in survival between pancre-
atic (n = 18) and non-pancreatic cases (n = 12) (p = 0.851,
figure 4C). These groups were comparable with respect to
tumour diameter (median 2.5 and mean 2.4 cm for both
groups), and the equal survival was not due to less fre-
quent lymph node metastasis among pancreatic cases
(positive lymph nodes in 15/18 pancreatic compared to
6/12 non-pancreatic cases).
Starting with all the histopathologic factors in the base
model for multivariable analysis, backward variable selec-
tion thus resulted in a final model that did not include
tumour origin (table 3). Only lymph node status, vessel
involvement and tumour diameter independently pre-
dicted the prognosis after resection of pancreatobiliary
type periampullary adenocarcinoma. The final model
obtained from stepwise backward analysis was confirmed
by repeating variable selection with forward stepwise
analysis. Although perineural infiltration also seemed to
be an important prognostic factor in univariate analysis,
this factor did not independently predict survival, due to
a strong association with lymph node metastasis (p =
0.002), vessel involvement (p < 0.001), and tumour
diameter (p = 0.024).
Validation of main conclusions in an independent dataset
We finally validated our main findings by performing a
separate analysis of histopathologic prognostic factors in
the historical control group consisting of patients oper-
ated in our institution before standardization of his-
topathologic assessment. Among these patients, 73 and
26 were upon reevaluation of the histologic slides found
to have pancreatobiliary and intestinal differentiation,
respectively. Tumour origin for all 99 cases was classified
as ampullary (n = 23), duodenal (n = 14), distal bile duct
(n = 10), and pancreatic (n = 52).
In univariate survival analysis, pancreatobiliary type of
differentiation (p < 0.001) and pancreatic tumour origin
(pancreatic versus ampullary, p = 0.03) both predicted a
poor prognosis. Adjusting for maximum tumour diame-
ter, lymph node and resection margin involvement,
degree of differentiation, and whether there was presence
of perineural infiltration, the histologic type of differenti-
ation remained highly significant (p < 0.001; HR 2.7; 95%
CI 1.5–4.9). In contrast, although approaching signifi-
cance, tumour origin did not significantly predict the
prognosis after adjustment for these other factors (pancre-
atic versus ampullary, p = 0.10; HR 1.6; 95% CI: 0.9–2.9).
In the subgroup analysis including only pancreatobiliary
differentiated tumours (n = 73), stepwise variable selec-
tion resulted in a final multivariable model in which
Table 3: Survival analysis of histopathologic prognostic factors in pancreatobiliary resections (n = 67)
p-value
HR 95% CI Univariate Multivariable
Pancreatic tumour origin (pancreatic vs non-pancreatic) 2.3 1.3–4.0 0.004
pT stage (pT3 or pT4 vs pT1 or pT2) 2.0 0.9–4.2 0.073
Resection margin involvement (R1 vs R0) 1.7 1.0–2.8 0.052
Lymph node involvement (N1 vs N0) 3.0 1.6–5.4 < 0.001 0.007
Poor differentiation (yes vs no) 1.6 0.9–2.6 0.094
Vessel involvement (yes vs no) 3.1 1.8–5.3 < 0.001 0.035
Perineural infiltration (yes vs no) 2.8 1.4–5.5 0.003
Tumour size (continuous, measured in cm) 1.7 1.3–2.1 < 0.001 < 0.001
HR, hazard ratio. HR > 1 indicates increased probability of death
CI, confidence interval
Table 2: Multivariable Cox regression analysis of histopathologic prognostic factors in periampullary adenocarcinomas (n = 114)
HR 95% CI p-value
Histologic type pancreatobiliary (vs intestinal) 3.1 1.8–5.1 < 0.001
Lymph node involvement N1 (vs N0) 2.5 1.5–4.4 < 0.001
Vessel involvement involved (vs not involved) 1.9 1.2–3.1 0.012
Tumour size diameter (measured in cm) 1.3 1.1–1.5 0.011
HR, hazard ratio. HR > 1 indicates increased probability of death compared to the reference group (for categorical variables) or compared to each 
increase of one cm in tumour size (continuous variable)
CI, confidence interval
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Pancreaticoduodenectomy for pancreatobiliary type periampullary adenocarcinoma: (A) Univariate survival for patients with p obiliary type periampull ry adenocarcinomas (n = 67) o iginati g in ampulla n = 13), d s al bile duct (n = 16), and pan-creas (n = 38) (p = 0.009)Figu  4
Pancreaticoduodenectomy for pancreatobiliary type periampullary adenocarcinoma: (A) Univariate survival for 
patients with pancreatobiliary type periampullary adenocarcinomas (n = 67) originating in ampulla (n = 13), distal bile duct (n = 
16), and pancreas (n = 38) (p = 0.009). (B) Boxplot of maximum tumour diameter in the same 67 tumours with pancreatobil-
iary differentiation (p < 0.001, pancreatic versus non-pancreatic). (C) Survival for patients with non-pancreatic (n = 12, of which 
6 ampullary and 6 biliary) and pancreatic (n = 18) tumours of comparable size (2 cm  maximum diameter  3 cm) (p = 0.851).
Patients at risk
pancreatic 18 12 6 4 1 0
non-pancreatic 12 7 4 2 2 2
Patients at risk
ampulla 13 8 6 4 4 3
distal bile duct 16 14 10 5 5 5
pancreas 38 22 8 5 2 0
A
C
B
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lymph node status (N1 versus N0, p < 0.001; HR 3.4; 95%
CI: 1.9–6.0) was confirmed to independently predict the
prognosis, adjusting for grade of differentiation (high/
moderate versus low, p = 0.002; HR 2.6; 95% CI 1.4–4.8)
and resection margin status (R1/2 versus R0, p = 0.011;
HR 1.9; 95% CI 1.2–3.2). Although significant in univar-
iate analysis (p = 0.021), tumour diameter was not con-
firmed to independently predict survival in this cohort,
possibly due to the small size of these tumours (mean
diameter 2.1 cm; 95% CI 1.9–2.4) and a significant asso-
ciation between tumour diameter and lymph node status
(p = 0.04). Finally, after stepwise variable selection,
tumour origin and perineural infiltration did not remain
in the final multivariable model evaluating histopatho-
logic factors of pancreatobiliary differentiated periampul-
lary adenocarcinomas, in accordance with the results from
the study group analysis.
Discussion
In the present study, we evaluated the prognostic impor-
tance of the two main histologic types of differentiation,
pancreatobiliary and intestinal types, in presumed cura-
tive resections for pancreatic head adenocarcinomas. We
found that the pancreatobiliary histologic type of differen-
tiation was independently associated with a poor progno-
sis, while tumour origin did not significantly predict
survival when adjusting for other histopathologic prog-
nostic factors. In pancreatobiliary type adenocarcinomas,
survival depended on factors related to the disease stage
(tumour size and regional lymph node involvement), but
not on the anatomic structure of origin. The main conclu-
sions from this study were confirmed by analysis in an
independent dataset.
For multiple reasons, we suggest that determination of the
histologic type of differentiation is a useful adjunct to
classification of the anatomical site of origin in periamp-
ullary tumours. Failure to reach a precise diagnosis of
tumour origin may lead to false assumptions regarding
long-term survival [2,7,10]. Periampullary anatomy may
be distorted by carcinoma or affected by inflammation
and fibrosis [9]. The normal ampulla, defined as the junc-
tion between the distal bile duct and the main pancreatic
duct, has a variable length and is absent in a large propor-
tion of the normal population [9]. Resected ductal pancre-
atic adenocarcinomas in the pancreatic head typically
have a mean diameter of ~3 cm[1], and may involve the
entire ampullary region [5]. Determination of tumour ori-
gin should therefore be standardized and include a sec-
tion parallel to (and including) the ductal structures in
order to evaluate the tumour's relation to the ductal anat-
omy. However, even with standardized evaluation, inter-
observer variability may be considerable unless clinical
and macroscopic data is also emphasized.
The present study is the first report on the distribution of
pancreatobiliary and intestinal type differentiation in a
cohort of resected adenocarcinomas of all periampullary
locations. With respect to ampullary tumours, it has been
known for more than a decade that these may have either
"intestinal" or "pancreatobiliary" histologic type of differ-
entiation [13], and that the intestinal type has a signifi-
cantly better prognosis [7,11-14]. Intestinal type biliary
tract [15] and pancreatic [16] carcinomas have also been
reported, but there is sparse data comparing pancreatobil-
iary type adenocarcinomas of these three different origins
[19-21]. Although many studies have compared ductal
adenocarcinomas of different periampullary origin [19-
22], most studies do not state specifically whether intesti-
nal type ampullary adenocarcinomas were excluded in
such comparisons. It should be noted that ductal adeno-
carcinoma is not synonymous with pancreatobiliary type
of histology, since it has recently been shown that ductal
pancreatic carcinomas may have features of intestinal dif-
ferentiation [16]. Pancreatobiliary ampullary carcinomas
that involve the pancreas may be indistinguishable from
pancreatobiliary pancreatic carcinomas that extend into
the ampulla [2,8], and low ratios of ampullary versus peri-
ampullary adenocarcinomas in many studies might reflect
a tendency towards misclassification of advanced pancre-
atobiliary type ampullary carcinomas as ductal pancreatic
carcinomas.
An explanation for the often reported more favourable
prognosis in non-pancreatic versus pancreatic carcinoma
could therefore be that comparison has not been strictly
limited to pancreatobiliary type adenocarcinomas. The
reason why there are prognostic differences between
equally advanced non-pancreatic and pancreatic adeno-
carcinomas may simply be that the latter more often has a
pancreatobiliary type of histologic differentiation [7].
Thus, the question whether survival differences between
pancreatic and non-pancreatic pancreatobiliary type ade-
nocarcinomas should be attributed to disease stage or
biology, or both, has not been definitely answered [2].
The present study suggests that survival differences
between periampullary adenocarcinomas of comparable
size are more dependent on the histologic type of differ-
entiation than on the anatomic origin.
In the UICC/AJCC classification of pancreatic head malig-
nancies, adenocarcinomas originating from the peri-Vate-
rian duodenum, the ampulla of Vater, the distal bile duct,
and the ductal pancreatic tissue are considered separate
entities [23,24], and the TNM staging criteria are different
for each origin. However, since adenocarcinomas arising
from the peri-Vaterian duodenum and the ampulla of
Vater may be indistinguishable [7], and since it may also
be difficult to discriminate between pancreatobiliary dif-
ferentiated ampullary and distal bile duct adenocarcino-
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mas [15], pT stage might be classified according to
inappropriate anatomic location. Furthermore, pT1 in
ductal pancreatic carcinoma includes tumours with maxi-
mum diameter up to 2 cm, while pT1 in ampullary carci-
nomas includes only small tumours not invading either
the duodenum (pT2) or the pancreas (pT3). A relatively
large pancreatic tumour could therefore still be at pT1
stage compared to a small ampullary tumour extending
into the duodenum, thus classified as pT2 (or even
extending into the pancreatic tissue, thus classified as
pT3). Importantly, pT stage was the factor with the lowest
p-value both in univariate and multivariable survival
analysis of all periampullary adenocarcinomas as well as
in the subgroup of pancreatobiliary differentiated adeno-
carcinomas. The present study therefore demonstrates
that individual factors related to tumour stage are more
reliable than pT (or TNM) stage group in multivariable
analysis of prognostic factors in pancreatic head carcino-
mas.
Conclusion
Pancreatobiliary versus intestinal type of differentiation
independently predicts poor prognosis after pancreati-
coduodenectomy for periampullary adenocarcinoma. In
pancreatobiliary type periampullary adenocarcinoma,
lymph node involvement, vessel involvement, and
increasing tumour diameter were adverse predictors of
survival in the present study.
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